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Abstract
BACKGROUND: The World Health Organization (WHO) recognizes cardiovascular diseases 
(CVD), such as high blood pressure (hypertension; HBP), coronary heart disease (e.g. 
myocardial infarction), cerebrovascular disease (stroke) and heart failure, as the major cause 
of death globally. Furthermore, CVD are multifactorial traits with a steeply rising prevalence 
worldwide, determined by a complex interplay of interactions between genome and 
environment, which renders their hereditary analysis a complicated task. Our previous studies 
in the founder population of French-Canadian families from the Saguenay-Lac-Saint-Jean 
(SLSJ) region of Quebec revealed the largest set of significantly  linked loci to hypertension 
and its metabolic components [1, 2].
HYPOTHESIS AND OBJECTIVE: Since our preliminary  findings suggest that early 
mortality from CVD has genetic and environmental factors, we hypothesize that our 
population will have distinct characteristics from diseases with and without fatal outcomes 
(FO and NFO, respectfully), especially in relation to CV cause. Our objectives are to analyze 
morbidity causes, their temporal characteristics and their clustering in the hypertensive 
families with or without obesity from the SLSJ region, using hospital, civic death registries 
and genealogical records from 1950 to the present. We want to describe and study FO and 
compare them to NFO.
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RESULTS: In total, we identified 3,654 diagnosis from FO and NFO in 343 participating 
subjects. For FO, we report: (1) 299 participants suffered from diseases of the circulatory 
system with a grand total of 1,103 diagnosis, 555 outcomes and 247 first outcomes; (2) 333 of 
the participating subjects were affected by non-CV systems with a total of 1,536 diagnosis, 
195 outcomes and 107 first outcomes; (3) all other diseases were responsible for a total of 81 
diagnosis, 30 outcomes and 11 first outcomes in 62 of the participating subjects; and for NFO: 
(1) the circulatory system affected 105 of the participating subjects with a total of 156 
diagnosis; (2) non-CVD, 53 of participating subjects with a total of 60 diagnosis; (3) all other 
diseases were found in 252 of participating subjects with a total of 718 diagnosis. For FO, 109 
of 333 affected subjects by non-CVD and 58 of 62 by all other diseases had also a concomitant 
CVD. We were able to show characteristics from both FO and NFO. In both first outcomes 
and total outcomes, CVD predominated over non-CV and all other diseases. When examining 
CV co-affection with non-CV or all other diseases, 67.1% of our sample population was 
affected by CV FO. In fact, our sample showed a threefold risk increase in developing CVD 
(p<0.0001; χ2=1,575.348) when compared to the general population of SLSJ, while it 
diminished by  half for non-CVD (p=0.0006; χ2=11.834). Finally, the relative risk for 
developing malignancies decreased by half in our sample in contrast to the same region.
CONCLUSION: This 11 year follow-up study provided a unique insight into affections for 
both FO and NFO. When looking at malignancies in conjunction with CVD, this risk grew 
twofold in our sample.
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KEY WORDS: Cardiovascular diseases, diagnosis, outcomes, first outcomes, hypertension, 
cancer, diseases with mortality, disease without mortality.
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Résumé
PROBLÉMATIQUE: L’Organisation Mondiale de la Santé (OMS) considère les maladies 
cardiovasculaires (MCVs) comme l'hypertension, la maladie coronarienne (par exemple, 
infarctus du myocarde), l'insuffisance cardiaque ainsi que les accidents cérébrovasculaires, 
parmi les principales causes de mortalité dans le monde. Les MCVs sont  des maladies 
multifactorielles caractérisées par des interactions complexes entre le génome et 
l'environnement et dont la prévalence augmente rapidement dans toutes les populations du 
globe, ce qui vient compliquer d'autant l'étude de leurs bases héréditaires. Nos études 
précédentes sur la population fondatrice des familles Canadiennes-françaises de la région du 
Saguenay-Lac-Saint-Jean (SLSJ) au Québec ont permis d’obtenir une carte des loci 
significativement liés à des déterminants qualitatifs et quantitatifs de l’hypertension et ses 
déterminants métaboliques [1, 2].
HYPOTHÈSE ET OBJECTIF: Puisque nos données préliminaires nous suggèrent que la 
mort prématurée consécutive aux MCVs possède des composantes génétique et 
environnementale, notre hypothèse de départ est que les maladies avec occurrences fatales et 
non fatales (OF et ONF, respectivement) ont  des caractéristiques distinctes, surtout  lorsqu’en 
lien avec le système CV. Pour réaliser ce projet, nos objectifs sont d’analyser les causes de 
morbidité/mortalité d’hypertendus avec ou sans obésité chez des familles de la région du 
SLSJ. Nous accomplirons ceci en interrogeant les registres des hôpitaux et de l'état civil de 
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même que les données généalogiques de 1950 jusqu'à maintenant. Nous voulons décrire et 
étudier les OF pour les comparer aux NFO.
RÉSULTATS: Nous avons identifié un total de 3,654 diagnostiques appartenant aux OF et 
ONF chez les 343 sujets étudiés. Pour les OF, nous avons trouvé que: (1) un grand total de 
1,103 diagnostiques du système circulatoire ont affecté 299 sujets avec 555 occurrences et 247 
premières occurrences; (2) 333 des sujets participants ont reçu 1,536 diagnostiques non-CV 
avec 195 occurrences et 107 premières occurrences; (3) 62 diagnostiques de toutes autres 
causes chez 62 des sujets participants avec 81 occurrences et 11 premières occurrences. Pour 
les ONF: (1) 156 diagnostiques du système circulatoire ont affecté 105 sujets; (2) 60 
diagnostiques de causes non-CV chez 53 des sujets; (3) et 718 diagnostiques de toutes autres 
causes chez 252 des sujets. Pour les OF, 109 des 333 sujets affectés par les maladies non-CV 
et 58 des 62 par toutes autres maladies étaient atteints simultanément par des MCV. Nous 
avons décrit les caractéristiques des maladies avec occurrences fatales et non fatales. Les 
MCVs prédominaient dans les résultats des premières occurrences et occurrences totales 
tandis que les maladies non-CV étaient les plus élevées pour les diagnostiques. De plus, les OF 
CV ont affecté 67.1% de notre échantillon de population, incluant les sujets co-affectés par les 
maladies non-CV ou de toutes autres causes. En fait, nos sujets ont un risque trois fois plus 
élevé de développer des MCVs (p<0.0001; χ2=1,575.348), tandis qu’il diminue de moitié 
pour les maladies non-CV comparativement au reste de la population du SLSJ (p=0.0006; 
χ2=11.834). Enfin, le risque de développer des tumeurs malignes est diminué de moitié dans 
notre échantillon comparativement à l’incidence régionale.
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CONCLUSION: Cette étude a apporté une nouvelle perspective sur les OF et ONF chez nos 
sujets de la région SLSJ du Québec après 11 ans. Quand on observe ces résultats en 
conjonction avec les MCVs, ce risque double.
MOTS CLEFS: Maladies cardiovasculaires, diagnostiques, occurrences, premières 
occurrences, hypertension, cancer, occurrences fatales, occurrences non fatales.
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Introduction
Before getting into the core of this thesis, we wanted to give a brief overview of the study 
dealing with fatal as well as non-fatal outcomes and how they  are related to cardiovascular 
diseases (CVD).
Both national and international statistics classify CVD as a leading cause of morbidity and 
mortality worldwide. This particularly refers to the founder French-Canadian population of 
Quebec’s Saguenay-Lac-Saint-Jean (SLSJ) region. Due to its historical background, the 
recruited subjects from this population offer us the unique opportunity  to study  morbidity 
characteristics related to CV outcomes.
Bearing this in mind, the basis of this research will be discussed in the “Literature 
Review” (Chapter II). This will begin with more detailed statistics concerning CVD on a 
global level and focus on the SLSJ region. In addition, we will introduce and elaborate on:
(a) The concept of genes and environment interaction;
(b) Cancer and CVD;
(c) The previously mentioned major causes of morbidity and mortality;
(d) CV risk factors;
(e) Synaptic plasticity in CVD.
In fact, these concepts help to comprehend the numerous results collected during this study. 
Lastly, we present the description of the project, hypothesis and objectives.
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In the third Chapter (“Methods”) we give a detailed explanation of the project’s phases. We 
will address the ethics behind it and detail the population of study, i.e. family cohort, 
phenotyping and probands. Furthermore, we show the stages involved in the design for data 
compilations, various disease criteria, followed by the result calculations and statistics.
Chapters IV (“Results) and V (“Discussion”) will present and discuss the data gathered 
following a novel classification method: fatal and non-fatal outcomes. We will examine the 
importance of CVD, non-CVD (e.g. cancer, etc.) and all other diseases (e.g. neurological 
disorders, etc.) for each category. Moreover, we will address the limitations of the current 
study. Finally, we will show the relative risk calculated and the degree of significance with Chi 
square (χ2) test for CVD versus other diseases.
We will complete this thesis with a short conclusion about our work and future perspectives 
(Chapter VI).
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CHAPTER II:
Literature Review
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Literature Review
2. CARDIOVASCULAR DISEASES (CVD)
2.1. DEFINITION
The World Health Organization (WHO) defines CVD as “caused by disorders of the heart and 
blood vessels, including coronary heart disease (CHD; myocardial infarction (MI), heart 
failure (HF)), cerebrovascular diseases (CBVD; stroke), raised blood pressure (hypertension; 
HBP), peripheral artery disease, rheumatic heart disease, congenital heart disease and HF” [3]. 
Furthermore, the WHO recognizes them as the number one cause of death globally, in both 
children and adults, and estimates that, by the year 2030, CVD (mainly  heart  disease and 
stroke) will kill close to 23.6 million people [4-6]. In Western Countries, such as the United 
States of America (USA) and Canada, the overall mortality  rates caused by  CVD have 
decreased over the last decade yet their burden remains high [7, 8]. Actually, the Public Health 
Agency of Canada totalized the costs for CVD at $22.2 billion while the USA estimates that, 
in 2010, the direct and indirect costs will amount to $503.2 billion [7-9].
2.2. STATISTICS
2.2.1.CANADA
In 2004, CVD were the first cause of Canadian deaths, amounting to 72,743 deaths or 
32.1% of all deaths and surpassing neoplasms in second place with 68,322 or 30.2% 
(Figure 1A) [8]. During 2005-2006, they were the highest  cause for patient 
hospitalization (16.9%) and length of stay in hospital (17.1%) compared to all diagnosis. 
30
The 2007 statistics on the provincial deaths from CVD portrays their high prevalence 
throughout Canada, 30% on average, except for Nunavut, which has the lowest one with 
12.4% (Figure 2A) (Statistics Canada 2010).
2.2.2.QUEBEC
The updated data of May 2010 by the Institut de la statistique du Québec (ISQ) in the 
French-Canadian Province of Quebec demonstrates, from the years 2000 to 2009, the 
overall number of deaths from CVD decreased by 2,305 [10]. In fact, the adjusted 
mortality rate went down from 400 deaths per 100,000 people in 1981 to less than 150 in 
2008 [11]. Nevertheless, it is estimated that they affect more than 6% of the Quebec 
population. As one of the lowest  CV death prevalence in Canada, Quebec maintains a 
favorable position when compared to the other provinces where, in contrast, an 
estimated 25.2% deaths are caused by CVD (n=14,421; Figure 2B) [10]. Moreover, only 
the neoplasms deaths surpass CVD deaths by 8.5%, making them, in the case of Quebec, 
the second cause of all deaths. Ischemic heart diseases were the major CVD cause with 
13.2%. Notwithstanding this encouraging data, the overall mortality from CVD still 
amounts to an estimated 709 potential lost lives per 100,000 people, which will also 
have a heavy impact on cost and usage of the health care system [11].
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Figure 1. Leading causes of death in 2004 Canada [8]. The total number of deaths from all causes = 
226,584.  *Other ischemic heart disease = ischemic heart disease - heart attack. †CBVD excludes transient 
ischemic attacks. ‡Other CVD = circulatory disease–other ischemic heart disease–heart attack–CBVD. §Other = 
all causes–[respiratory disease, all CVD, accidents/poisoning/violence, neoplasms, infectious diseases, and 
diabetes]. Original Source: Chronic Disease Surveillance Division, Centre for Chronic Disease Prevention and 
Control,  Public Health Agency of Canada, using data from the Vital Statistics Database (Statistics Canada). 
Reproduced with permission from the Minister of Health, 2013.
* Other ischemic heart disease = ischemic heart disease - heart attack.  † Cere-
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Figure 2. A) Deaths caused by CVD in each Canadian province in 2007. The total number of 
deaths in Canada from CVD = 69,503; from all causes = 235,217. Percentage takes into account the population 
sample size from each province giving a better picture of the prevalence of CVD. Small population: Yukon, 
North-Western Territories and Nunavut deaths from CVD = 54, 47 and 16, respectively. Original Source: 
Statistics Canada [12]. B) Leading causes of death in Quebec, 2009. The total number of deaths from 
all causes = 57,200. *Ischemic heart disease: Total deaths = 7,565—from which 4,359 are due to acute and 
subsequent myocardial infarction. †Diseases of arteries, arterioles and capillaries: Total deaths = 855—from 
which 211 are due to atherosclerosis. §Other = all causes–[respiratory diseases, all CVD, neoplasms and 
diabetes]. Original Data Source: Institut de la statistique du Québec [10]. NOTE: Small discrepancy in the data 
from Figures 2A and 2B exists due to the different dates the two organisms close their respective ‘death’ files for 
analysis (explained in a email correspondence with Miss Caroline Guillemette, Institut de la statistique du 
Québec.
2.2.3.SAGUENAY-LAC-SAINT-JEAN REGION
The extensively  studied French Canadian population of the Saguenay-Lac-Saint-Jean 
(SLSJ) region of Quebec is at  high risk for CVD [1, 13-18]. Recent statistics obtained 
between 2002 and 2006 concerning the mortality by cause (adjusted rate per 100,000) 
depict neoplasms as the first cause of death, which is followed by  CVD as the second 
cause for this region (Table I) [19]. Even though the estimated life expectancy at birth 
has increased since the last census [13] (1994-1998) for men and women to 76.5 and 
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81.6, respectively, the ISQ estimates that  these values remain amongst  the lowest within 
the province for the years 2005-2007. The data also show a higher prevalence of death 
by all causes especially  in SLSJ when compared to the whole Province of Quebec. 
Furthermore, we observe in SLSJ high onset of ischemic heart diseases and especially 
for CBVD and diseases of arteries, arterioles and capillaries (Table II) [19].
Table I. Adjusted mortality rate per 100,000 by cause (2002-2006) of the SLSJ region 
compared to the whole Province of Quebec [19].
Causes Quebec SLSJ Cases/year
All 679.2 718.6 2,058
Neoplasms 221.7 247.5 726
Diseases of the circulatory system 190.0 184.9 525
Diseases of the respiratory system 58.0 64.3 181
External causes of morbidity and mortality 45.4 58.8 164
Endocrine, nutritional and metabolic diseases 28.9 27.3 79
Table II. Adjusted mortality rate per 100,000 caused by diseases of the circulatory 
system, CVD, (2002-2006) of the SLSJ region compared to the whole Province of Quebec 
[19]. 
Diseases of the circulatory system Quebec SLSJ Cases/year
Ischemic heart disease 105.4 92.7 265
Acute and subsequent MI 59.9 52.6 152
CBVD 34.2 40.7 115
Diseases of arteries, arterioles and capillaries 9.9 12.2 35
34
Diseases of the circulatory system Quebec SLSJ Cases/year
HF 11.6 9.7 27
Total 221 207.9 594
The epidemiological data of the SLSJ also reveal that, in the cases of morbidities, 
diseases of the circulatory system are the main cause of hospitalization in this region 
(Table III) [19].
Table III. Adjusted hospitalization rate per 10,000 by main diagnosis (2006-2009) of the 
SLSJ region compared to the whole Province of Quebec [19].
Causes Quebec SLSJ Cases/year
All hospitalization by main diagnosis 762.3 985.3 26,872
Malignant neoplasms 60.9 74.0 2,019
Diseases of the circulatory system 123.9 142.2 3,878
Diseases of the respiratory system 54.8 68.3 1,862
Diseases of the gastrointestinal tract 76.9 123.0 3,355
Non-intentional traumas 81.7 119.5 3,258
2.3. GENES AND ENVIRONMENT
Before Sir Archibald E. Garrod proposed his theory  on genetics in the early twentieth century 
[20], diseases were thought to affect people arbitrarily rather than having a direct or indirect 
cause due to genetic factors found in our deoxyribonucleic acid (DNA) blueprint  [21]. In fact, 
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when people died of an unknown origin, their death was adjudged by the coroner as “death by 
natural cause”. However, we now understand that the underlying causes of a significant 
number of diseases are due to complex interactions such as “gene-gene” and “gene-
environment”. CVD are multifactorial traits that do not display a clear Mendelian type pattern 
of inheritance [2, 22, 23], which has challenged the paradigms of classical genetics. Today, the 
notion of genetic susceptibility is firmly established and we realized that deaths by “natural 
causes” were heavily over-rated.
2.4. CANCER AND CVD
Neoplasms and CVD account for more than 60% of all deaths in western countries and can be 
referred to as “age-related diseases” (Figures 1 and 2B) [24]. After reviewing the literature 
until the late 1990s, Hamet explains how the previously  thought “weak” association between 
Hypertension and Cancer is actually being revised and increasing significantly [25]. With the 
knowledge surrounding cellular biology  and the complex genomic interactions of complex 
diseases increasing, the recently published “diseasome” clearly shows how overlapping 
pathophysiological pathways are involved in both HBP and cancer (Figure 3) [25, 26].
Furthermore, the debate whether there exists an association between cancer and HBP began 
more than forty years ago with Dyer et al.’s prospective study and continued on since [25, 
27-39]. Differences in the various studies may lie in the many factors analyzed, especially 
differences in the population size, control and affected groups, and parallel evaluation of HBP 
in their subjects. In fact, it  is also questionable whether hypertension may be secondary to the 
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carcinoma, i.e. the malignancy would be the cause of HBP, or they  would just have similar risk 
factors [34, 40]. In some cases, this relationship would be quite difficult to determine.
In the last decade, HBP treatment with antihypertensive drugs (e.g. diuretics and Angiotensin 
type II receptor blockers), has been suspected to be associated with a higher risk to develop 
certain types of carcinomas, such as renal cell and breast [25, 28, 31, 33, 35-37, 39, 41-44], 
and even modestly increase the risk of new cancer diagnosis [45]. In fact, hypertension is not 
only associated in men (not women) with an increased risk of death from cancer but also to the 
risk of developing it [46, 47].
2.5. EARLY MORTALITY
The term early mortality  refers to a fatal event (e.g. CVD) that occurred prematurely, 
prematurely being defined as having occurred between ages of 25 to 55 for men and 25 to 65 
for women [13]. Furthermore, premature death due to CVD accounted for $9.3 billion in loss 
of productivity  in Canada [8]. In 2004, mortality  rates began to increase dramatically among 
men at age 45 (1 in 5) and women at  age 55 (1 in 4) compared to 1 in 8 between 35 and 44 
years of age [8].
2.6. RISK FACTORS FOR CVD
While the risk factors for CVD are debatable, USA’s Seventh Report of the Joint National 
Committee classifies them in 10 major categories: hypertension, cholesterol (CHOL), age, sex, 
diabetes mellitus (DM), estimated glomerular filtration rate (eGFR), family history, 
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microalbuminuria, obesity  and lifestyle [48]. Components of the metabolic syndrome (MSY) 
previously  mentioned, such as HBP, DM  and CHOL, are especially crucial when considering 
the risk factors for CVD. The prevalence of these predisposition elements is responsible for 
the CVD epidemic worldwide. In fact, the WHO considers this prevalence to lead to a higher 
incidence of CVD highly associated with CV mortality [4]. Unfortunately, they are rarely 
identified and remain untreated [49], which may lead to deadly  diseases, such as stroke, 
ischemic heart diseases, left ventricular hypertrophy (LVH), renal dysfunction and even death 
[48, 50-52]. Finally, investigations on Canadian vascular health done between 1985 - 1990 
revealed a staggering 41% and 33% of men and women, respectively, aged from 18 to 74 
years, had at least 2 major risks factors for CVD, such as dyslipidemia (DLP) and HBP [53].
In fact, Goh, Barabasi and their colleagues have conceptualized the human genetic disorders 
and their corresponding disease genes to show how they  might be related to one another at  a 
higher level of cellular and organismal organization (Figures 3) [26]. This might help 
understand how the CVD risk factors influence each other and the outcomes of CV events and 
even mortality.
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Figure 3. “The human disease network” [26]. Zoomed section of the original figure  pertaining to this 
thesis. Full original figure from Goh’s paper; Note: Original legend from figure - Each node corresponds to a 
distinct disorder, colored based on the disorder class to which it belongs. A link between disorders in the same 
disorder class is colored with the corresponding dimmer color and links connecting different disorder classes are 
gray. The size of each node is proportional to the number of genes participating in the corresponding disorder, 
and the link thickness is proportional to the number of genes shared by the disorders it connects. For a complete 
explanation of the details from the original figure with the names, colors and corresponding genes see the figure 
SI Fig. 13 from Goh et al. referred above. Copyright (2007) National Academy of Sciences, U.S.A.
2.6.1.HYPERTENSION
As one of the leading risk factors for mortality and disability, HBP is a major worldwide 
public-health issue due to its high frequency and concomitant risks for CV and kidney 
disease [54-56]. By 2025, Kearney  and her colleagues estimate that the world’s adults 
affected by HBP will rise from 1 billion in 2000 to 1.56 billion—29% of the global 
population [56, 57]. Furthermore, many people remain unaware of their HBP despite the 
progress of detection, even in western countries, such as Canada [58]. Criteria for HBP 
are systolic BP (SBP)/diastolic BP (DBP) ≥ 140/90 mmHg without treatment [48, 59], 
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Hypophosphatemia
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syndrome
969
Melnick-Needles
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Opremazole
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syndrome
Ovarioleukodystrophy
Pachyonychia
congenita
Paget
disease
Pallister-Hall
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UV-induced
skin damage
Velocardiofacial
syndrome
Virilization
1565
1580
Weaver
syndrome
Weyers
acrodental
dysostosis
WHIM
syndrome
Wolfram
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Supporting Information Figure 13 | Bipartite-graph representation of the diseasome. A disorder (circle) and a gene (rectangle) are connected if the gene is implicated in the disorder. The size of the circle represents the number of distinct genes associated with the disorder. Isolated disorders (disorders having no links to other disorders) are not shown. Also, only genes connecting disorders are shown.
Disorder Class
Disorder Name
Bone
Cancer
Cardiovascular
Connective tissue disorder
Dermatological
Developmental
Ear, Nose, Throat
Endocrine
Gastrointestinal
Hematological
Immunological
Metabolic
Muscular
Neurological
Nutritional
Ophthamological
Psychiatric
Renal
Respiratory
Skeletal
multiple
Unclassified
5233 Placental steroid sulfatase deficiency
5170 Ovarian hyperstimulation syndrome
4291 Cerebral cavernous malformations
3558 Ventricular fibrillation, idiopathic
3512 Total iodide organification defect
3260 Premature chromosome condensation w/ microcephaly, mental retardation
3229 Pigmented adrenocortical disease, primary isolated
3212 Persistent hyperinsulinemic hypoglycemia of infancy
3144 Optic nerve coloboma with renal disease
3037 Multiple cutaneous and uterine leiomyomata
2785 Hypoplastic left heart syndrome
2385 Creatine deficiency syndrome, X-linked
2354 Congenital bilateral absence of vas deferens
2327 Chronic infections, due to opsonin defect
1614 Yemenite deaf-blind hypopigmentation syndrome
1611 XLA and isolated growth hormone deficiency
1586 Weissenbacher-Zweymuller syndrome
1580 Warfarin resistance/sensitivity
1565 Vitamin K-dependent coagulation defect
1555 VATER association with hydrocephalus
1545 Unna-Thost disease, nonepidermolytic
1542 Ullrich congenital muscular dystrophy
1528 Trismus-pseudocomptodactyly syndrome
1526 Trifunctional protein deficiency
1519 Transposition of great arteries, dextro-looped
1518 Transient bullous of the newborn
1490 Thanatophoric dysplasia, types I and II
1476 Tauopathy and respiratory failure
1475 Tarsal-carpal coalition syndrome
1466 Sweat chloride elevation without CF
1456 Subcortical laminar heterotopia
1446 Stevens-Johnson syndrome, carbamazepine-induced
1438 Stapes ankylosis syndrome without symphalangism
1432 Spondylocarpotarsal synostosis syndrome
1414 Solitary median maxillary central incisor
1401 Skin fragility-woolly hair syndrome
1396 Silver spastic paraplegia syndrome
1383 Severe combined immunodeficiency
1376 Sensory ataxic neuropathy, dysarthria, and ophthalmoparesis
1361 Schwartz-Jampel syndrome, type 1
1347 Sandhoff disease, infantile, juvenile, and adult forms
1335 Robinow syndrome, autosomal recessive
1325 Rhizomelic chondrodysplasia punctata
1297 Pyruvate dehydrogenase deficiency
1267 Prolactinoma, hyperparathyroidism, carcinoid syndrome
1265 Progressive external ophthalmoplegia with mitochondrial DNA deletions
1263 Prion disease with protracted course
1239 Pneumothorax, primary spontaneous
1238 Pneumonitis, desquamative interstitial
1232 Pituitary ACTH-secreting adenoma
1229 Pigmented paravenous chorioretinal atrophy
1227 Pigmentation of hair, skin, and eyes, variation in
1183 Papillary serous carcinoma of the peritoneum
1174 Pallidopontonigral degeneration
1164 Osteoporosis-pseudoglioma syndrome
1153 Ossification of the posterior longitudinal spinal ligaments
1140 Oligodontia-colorectal cancer syndrome
1133 Oculofaciocardiodental syndrome
1119 Norwalk virus infection, resistance to
1113 Noncompaction of left ventricular myocardium
1105 Newfoundland rod-cone dystrophy
1104 Nevus, epidermal, epidermolytic hyperkeratotic type
1096 Neurofibromatosis-Noonan syndrome
1090 Neural tube defects, maternal risk of
1080 Nephrogenic syndrome of inappropriate antidiuresis
1057 Myokymia with neonatal epilepsy
1056 Myoglobinuria/hemolysis due to PGK deficiency
1050 Myelomonocytic leukemia, chronic
1016 Mitochondrial complex deficiency
1002 Methylcobalamin deficiency, cblG type
1001 Methionine adenosyltransferase deficiency, autosomal recessive
982 Melorheostosis with osteopoikilosis
969 Medullary cystic kidney disease
959 Mastocytosis with associated hematologic disorder
945 Mandibuloacral dysplasia with type B lipodystrophy
942 Malignant hyperthermia susceptibility
930 Lynch cancer family syndrome II
913 Lower motor neuron disease, progressive, without sensory symptoms
891 Leukoencephalopathy with vanishing white matter
868 Laryngoonychocutaneous syndrome
847 Keratosis palmoplantaria striata
845 Keratoderma, palmoplantar, with deafness
843 Keratitis-ichthyosis-deafness syndrome
833 Juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome
830 Jervell and Lange-Nielsen syndrome
809 Infundibular hypoplasia and hypopituitarism
803 Immunodysregulation, polyendocrinopathy, and enteropathy, X-linked
792 Hystrix-like ichthyosis with deafness
785 Hypoplastic enamel pitting, localized
780 Hypoparathyroidism-retardation-dysmorphism syndrome
734 Hyperkeratotic cutaneous capillary-venous malformations
733 Hyperkalemic periodic paralysis
727 Hyperferritinemia-cataract syndrome
701 Homozygous 2p16 deletion syndrome
699 Homocystinuria-megaloblastic anemia, cbl E type
679 High-molecular-weight kininogen deficiency
665 Hemosiderosis, systemic, due to aceruloplasminemia
646 Hearing loss, low-frequency sensorineural
626 Greig cephalopolysyndactyly syndrome
604 Glutathione synthetase deficiency
594 Glomerulocystic kidney disease, hypoplastic
584 Giant platelet disorder, isolated
558 Fuchs endothelial corneal dystrophy
549 Foveomacular dystrophy, adult-onset, with choroidal neovascularization
545 Focal cortical dysplasia, Taylor balloon cell type
544 Fluorouracil toxicity, sensitivity to
539 Fibular hypoplasia and complex brachydactyly
535 Fibrocalculous pancreatic diabetes
527 Fatty liver, acute, of pregnancy
474 Emery-Dreifuss muscular dystrophy
471 Elite sprint athletic performance
463 Dystransthyretinemic hyperthyroxinemia
461 Dyssegmental dysplasia, Silverman-Handmaker type
453 Dysalbuminemic hyperthyroxinemia
452 Dyggve-Melchior-Clausen disease
441 Dopamine beta-hydroxylase deficiency
439 Dissection of cervical arteries
438 Disordered steroidogenesis, isolated
434 Dilated cardiomyopathy with woolly hair and keratoderma
422 Dermatofibrosarcoma protuberans
418 Dentinogenesis imperfecta, Shields type
396 Cyclic ichthyosis with epidermolytic hyperkeratosis
379 Craniofacial-skeletal-dermatologic dysplasia
378 Craniofacial-deafness-hand syndrome
377 Craniofacial anomalies, empty sella turcica, corneal endothelial changes
357 Conotruncal anomaly face syndrome
347 Colonic aganglionosis, total, with small bowel involvement
344 Cold-induced autoinflammatory syndrome
329 Chylomicronemia syndrome, familial
320 Choreoathetosis, hypothyroidism, and respiratory distress
313 Cholesteryl ester storage disease
294 Cerebrovascular disease, occlusive
292 Cerebrooculofacioskeletal syndrome
287 Central hypoventilation syndrome
279 Cavernous malformations of CNS and retina
275 Carpal tunnel syndrome, familial
217 Bone mineral density variability
210 Blepharophimosis, epicanthus inversus, and ptosis
198 Beta-2-adrenoreceptor agonist, reduced response to
192 Beare-Stevenson cutis gyrata syndrome
182 Bannayan-Riley-Ruvalcaba syndrome
171 Attention-deficit hyperactivity disorder
162 Athabaskan brainstem dysgenesis syndrome
144 Arrhythmogenic right ventricular dysplasia
137 Apparent mineralocorticoid excess, hypertension due to
129 Anxiety-related personality traits
126 Anterior segment anomalies and cataract
117 Angiotensin I-converting enzyme
107 Analgesia from kappa-opioid receptor agonist, female-specific
96 Alternating hemiplegia of childhood
92 Alpha-thalassemia/mental retardation syndrome
87 Alpha-1-antichymotrypsin deficiency
77 Aldosterone to renin ratio raised
53 Adrenal hyperplasia, congenital
26 Achondrogenesis-hypochondrogenesis, type II
18 Acampomelic campolelic dysplasia
39
which can be managed relatively well with adequate therapy  (i.e. adjustment of 
antihypertensive medication, etc.).
HBP is a very complex multifactorial disease, which includes both monogenic and 
essential sub-categories depending on the basis of the mode of inheritance. The first 
type, known as ‘monogenic’ or Mendelian forms of hypertension, results from a single 
gene defect and, as such, is inherited in a simple Mendelian manner [51]. The second 
one, human essential hypertension, occurs from a complex interplay of of genetic 
mutations and environmental factors and is the most common form found in human 
population. This form exhibits cases of familial aggregation  without a clear pattern of 
Mendelian inheritance attributable to a single gene locus [51]. In fact, previous 
genealogical research in the geographically isolated population of French-Canadians 
origin provided the most detailed genome-wide set of highly  significant qualitative and 
quantitative linkage loci of hypertension and related traits [1, 17, 18].
Historically, the initial focus has been on DBP from evidence of clinical trial before 
shifting to SBP from observational studies as a stronger predictor of death in middle and 
older-aged populations [60-64]. More specifically, SBP rises throughout life, whereas 
DBP peaks at the fifth and sixth decades where it plateaus or even decreases afterwards 
[65]. However, it is not uncommon that cases arise with patients not only affected by 
HBP but other systemic diseases, such as DM, DLP or kidney diseases, which 
complicates both their obvious health status and the complexity  of their treatment. In 
40
fact, treatment of HBP in people with DM reduces premature death and disability  by up 
to 50% [59]. Furthermore, HBP is one of the major risk factors for CVD, such as MI and 
stroke, which may  lead to early death (Figure 4). Hypertensive subjects, with a positive 
family history  for CV death, are at higher risk for early mortality from CVD and specific 
quantitative trait loci demonstrate familial aggregation of HBP phenotypes [1, 48]. Thus, 
CVD are more frequent in hypertensive families than in normotensive ones.
Figure 4. Close view of the original figure “The human disease network” [26]. Copyright 
(2007) National Academy of Sciences, U.S.A.
Criteria for early mortality age-classification [13, 48] do not take into account HBP, 
which may lead to deadly CV outcomes. Little research has been done to identify  the 
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disease
Partington
syndrome
PCWH
Pelizaeus-Merzbacher
disease
Pendred
syndrome
Perineal
hypospadias
Peters
anomaly
Peutz-Jeghers
syndrome
Pfeiffer
syndrome
Pheochromocytoma
Pick
disease
Piebaldism
1229
Pilomatricoma
1232
Placental
abruption
Platelet
defect/deficiency
1239
Polycythemia
Polyposis
PPM-X
syndrome
Preeclampsia
Primary
lateral_sclerosis
1263
1267
Prostate
cancer
Proud
syndrome
Pseudoachondroplasia
Pseudohypoaldosteronism
Pseudohypoparathyroidism
Pyropoikilocytosis
1297
Rabson-Mendenhall
syndrome
Renal_cell
carcinoma
Retinal_cone
dsytrophy
Retinitis
pigmentosa
Retinoblastoma
Rett
syndrome
Rhabdomyosarcoma
Rheumatoid
arthritis
Rh-mod
syndrome
Rh-negative
blood_type
Rieger
syndrome
Ring_dermoid
of_cornea
Rippling_muscle
disease
Roussy-Levy
syndrome
Rubenstein-Taybi
syndrome
Saethre-Chotzen
syndrome
Salivary
adenoma
1347
SARS,
progression_of
Schizophrenia
Schwannomatosis
Sea-blue_histiocyte
disease
Seasonal
affective_disorder
Sebastian
syndrome
Self-healing
collodion_baby
Sepsis
1383
Sezary
syndrome
Shah-Waardenburg
syndrome
Shprintzen-Goldberg
syndrome
Sick_sinus
syndrome
1396
Simpson-Golabi-Behmel
syndrome
1401
SMED
Strudwick_type
1414
Somatotrophinoma
Spastic_ataxia
/paraplegia
Spherocytosis
Spinal_muscular
atrophy
Spinocereballar
ataxia
1432
Spondyloepiphyseal
dysplasia
Squamous_cell
carcinoma
Stargardt
disease
Stickler
syndrome
Stomach
cancer
Stroke
1456
Supranuclear
palsy
Supravalvar_aortic
stenosis
Syndactyly
Systemic_lupus
erythematosus
Tangier
disease
1476
T-cell
lymphoblastic
leukemia
Tetralogy
of_Fallot
1490
Thrombocythemia
Thrombocytopenia
Thrombophilia
Thyroid
carcinoma
Thyrotoxic
periodic
paralysis
Tietz
syndrome
Toenail
dystrophy,
isolated
1518
1528
Turcot
syndrome
1545
Urolithiasise
Usher
syndrome
Uterine
leiomyoma
van_Buchem
disease
1555
Ventricular
tachycardia
Vertical
talus
Viral
infection
Vitelliform
macular
dystrophy
Vohwinkel
syndrome
von_Hippel-Lindau
syndrome
Waardenburg-Shah
syndrome
Waardenburg
syndrome
Wagner
syndrome
WAGR
syndrome
Walker-Warburg
syndrome
Watson
syndrome
Wegener
granulomatosis
Weill-Marchesani
syndrome
1586
Williams-Beuren
syndrome
Wilms
tumor
Wiskott-Aldrich
syndrome
Witkop
syndrome
Wolff-Parkinson-White
syndrome
1614
Zlotogora-Ogur
syndrome
Adrenal
adenoma
Adrenal_cortical
carcinoma
Aneurysm,
familial_arterial
Autoimmune
thyroid
disease
Basal_cell
nevus_syndrome
Carcinoid_tumor
of_lung
Central_core
disease
Coronary
spasms
2385
2785
Macular
dystrophy
Medullary_thyroid
carcinoma
Pancreatic
agenesis
3212
3229
Thyroid
hormone
resistance
3512
3558
Combined
immunodeficiency
Multiple
malignancy
syndrome
Optic_nerve
hypoplasia/aplasia
5233
Renal
tubular
acidosis
Multiple
sclerosis
Renal
tubular
dysgenesis
ABCA1
ABCA4
ADA
ADRB2
AGRP
JAG1
AGTAGTR1
ALOX5
ALOX5AP
APC
APOA1
APOA2
APOB
APOE
APPFAS
AQP1
AR
STS
ATM
ATP1A2
ATP7A
BAX
CCND1
BCS1L
BDNF
BMPR1A
BRCA1
BRAF
BRCA2
C6
CACNA1A
CACNA1S
CACNB4
CASP8
CASP10
CASR
CAV3
RUNX1
CBS
CD36
CDH1
CDKN2A
CHRNA4
COL1A1
COL1A2
COL2A1
COL3A1
COL7A1
COL8A2
COL9A2
COL9A3
COL11A1
COL11A2
COMP
KLF6
COX15
CP
CPT2
CRX
CRYAB
NKX2-5
CTLA4
CTNNB1
CYP1B1
CYP2A6
DBH
ACE
DCTN1
DCX
DES
TIMM8A
COCH
NQO1
DMD
DSP
DSPP
SLC26A2
ECE1
EDN3
EDNRB
EGFR
EGR2
ELA2
ELN
EP300
EPHX1ERBB2
EYA4
ESR1
EYA1
F5
F7
FBN1
FCGR3A
FCMD
FGA
FGB
FGD1
FGFR1
FGFR3
FGFR2
FGG
FOXC1
FLNB
G6PD
GABRG2
GARS
GATA1
GCK
GCNT2
GCSL
GDNF
GJA1
GJB2
GJB3
GPC3
GNAI2
GNAS
GSS
MSH6
GYPC
GUCY2D
HEXB
CFH
HNF4A
HOXD10
HRAS
HSD11B2
HSPB1
HTR2A
IL2RG
IL10
IL13
INS
INSR
IPF1
IRF1
JAK2
KCNE1
KCNH2
KCNJ11
KCNQ1
KCNQ2
KIT
KRAS
KRT1
KRT10
LAMA3
LMNA
LOR
LPP
LRP5
SMAD4
MAPT
MATN3
MECP2
MEN1
MET
CIITA
MITF
MLH1 NR3C2
MPO
MPZ
MSH2
MSX1
MSX2
MUTYH
MXI1
MYF6
MYH6
MYH7
MYH8
MYH9
MYO7A
NBN
NDP
NDUFV1
NDUFS4
NF1
NF2
NOS3
NRL
NTRK1
OPA1
SLC22A18
PAFAH1B1
PARK2
PAX3
PAX6
PAX9
PDGFB
PDGFRA
PDGFRL
PDE6B
PDHA1
ENPP1
SLC26A4
PGK1
SERPINA1
PIK3CA
PITX2 PITX3
PLEC1
PLOD1
PLP1
PMP22
PMS2
PPARG
PRKAR1A
PRNP
PRODH
PSEN1
PTCH
PTEN
PTPN11
PTPRC
PVRL1
RAG1
RAG2
RASA1
RB1
RDS
REN
RET
RHAG
RHCE
RHO
RLBP1
RP1
RPGR
RPE65
RPS6KA3
RYR1
RYR2
SCN4A
SCN5A
SCNN1B
SCNN1G
SDHA
SDHBSDHD
SGCD
SHH
SLC2A2
SLC4A1
SLC6A4
SLC6A8
SLC34A1
SNCA
SOX3
SOX10
SPTA1
SPTB
STAT5B
ELOVL4
STK11
ABCC8
TAP2
TAZ
TBP
TCF1
TCF2
TG
TGFBR2
TGM1
THBD
TNF
TP53
TPO
TSHR
TTN
TTR
TYR
USH2A
VHL
VMD2
WAS
WT1
XRCC3
PLA2G7
HMGA2
DYSF
AXIN2
MAD1L1
RAD54L
IKBKG
TCAP
PTCH2
WISP3
BCL10
PHOX2B
LGI1
VAPB
MYOT
KCNE2
NR2E3
USH1C
FBLN5
POMT1
GJB6
SPINK5
CHEK2
ACSL6
CRB1
AIPL1
RAD54B
PTPN22
BSCL2
VSX1
FOXP3
PHF11
PRKAG2
NLGN3
CNGB3
RETN
RPGRIP1
NLGN4X
ALS2
CDH23
DCLRE1C
PCDH15
CDC73
OPA3
BRIP1
MASS1
ARX
FLCN
Abacavir
hypersensitivity
18
Acrocallosal
syndrome
Acrocapitofemoral
dysplasia
Acrokeratosis
verruciformis
Acromesomelic
dysplasia
53
Adrenoleukodystrophy
Adrenomyeloneuropathy
ADULT
syndrome
Agammaglobulinemia
AIDS
77
Aldosteronism
Alopecia
universalis
Alpers
syndrome
87
Alpha-actinin-3
deficiency
92
Alport
syndrome
Amelogenesis
imperfecta
Analbuminemia
107
Anderson
disease
Anhaptoglobinemia
Ankylosing
spoldylitis
Antley-Bixler
syndrome
Aplastic
anemia
Aromatase
deficiency
Arthrogryposis
162
Atransferrinemia
Atrichia w/
papular lesions
171
Bardet-Biedl
syndrome
BCG
infection
Beckwith-Wiedemann
syndrome
Bernard-Soulier
syndrome
Bethlem
myopathy
Blau
syndrome
210
Blepharospasm
Blue-cone
monochromacy
Bombay
phenotype
Bosley-Salih-Alorainy
syndrome
Brachydactyly
Buschke-Ollendorff
syndrome
Calcinosis,
tumoral
Campomelic
dysplasia
Cartilage-hair
hypoplasia
279
292
294
Ceroid
lipofuscinosis
Ceroid-lipofuscinosis
CETP
deficiency
Cholelithiasis
Cholestasis
313
Chondrocalcinosis
Chondrosarcoma
Chorea,
hereditary
benign
320
Chudley-Lowry
syndrome
329
Chylomicron
retention
disease
Ciliary
dyskinesia
CINCA
syndrome
Cleidocranial
dysplasia
Cockayne
syndrome
Codeine
sensitivity
344
Colorblindness
Congestive
heart
failure
Conjunctivitis,
ligneous
357
Coproporphyria
Craniometaphyseal
dysplasia
CRASH
syndrome
Crigler-Najjar
syndrome
Crohn
disease
Cystathioninuria
Cystic
fibrosis
Cystinuria
Darier
disease
Debrisoquine
sensitivity
Dental
anomalies,
isolated
Dent
disease
De Sanctis-Cacchione
syndrome
DiGeorge
syndrome
438
Dosage-sensitive
sex
reversal
Double-outlet
right ventricle
Down
syndrome
452
453
Dyskeratosis
Dysprothrombinemia
461
Dystonia
EEC syndrome
471
Ellis-
van Creveld
syndrome
Enchondromatosis
Erythremias
Erythrocytosis
Ewing
sarcoma
Exostoses
527
Fertile
eunuch
syndrome
535
Fibromatosisl
539
Fish-eye
disease
Fitzgerald factor
deficiency
544
545
Frontometaphyseal
dysplasia
Fumarase
deficiency
Gaucher
disease
584
Gilbert
syndrome
GM-gangliosidosis
Greenberg
dysplasia
626
Guttmacher
syndrome
Haim-Munk
syndrome
Hand-foot-uterus
syndrome
Harderoporphyrinuria
HARP
syndrome
Hay-Wells
syndrome
646
Heinz
body
anemia
HELLP
syndrome
Hemangioma
Hematuria,
familial_benign
Hemochromatosis
Hemoglobi_H
disease
Hemophilia
Heterotaxy
Heterotopia
Hex_A
pseudodeficiency
679
Homocysteine
plasma
level
699 701
Hoyeraal-Hreidarsson
syndrome
HPFH
HPRT-related
gout
H._pylori
infection
Hyalinosis,
infantile
systemic
Hydrocephalus
Hyperalphalipoproteinemia
Hyperandrogenism
Hyperbilirubinemia
Hyperekplexia
727
Hyper-IgD
syndrome
734
Hypermethioninemia
Hyperphenylalaninemia
Hyperprothrombinemia
Hypertrypsinemia
Hyperuricemic
nephropathy
Hypoaldosteronism
Hypochromic
microcytic
anemia
Hypogonadotropic
hypogonadism
Hypohaptoglobinemia
Hypolactasia,
adult
type
780
Hypophosphatasia
Hypophosphatemia
Hypophosphatemic
rickets
785
Hypoprothrombinemia
Inclusion
body
myopathy
Iron
overload/deficiency
Joubert
syndrome
Juberg-Marsidi
syndrome
Kanzaki
disease
Kartagener
syndrome
Kenny-Caffey
syndrome-1
Kininogen
deficiency
Langer
mesomelic
dysplasia
Laron
dwarfism
LCHAD
deficiency
Lead
poisoning
Leiomyomatosis
Leri-Weill
dyschondrosteosis
Lesch-Nyhan
syndrome,
891
Leydig
cell
adenoma
LIG4
syndrome
Limb-mammary
syndrome
Lipoprotein
lipase
deficiency
Longevity
Lowe
syndrome
Low renin
hypertension
Lymphangioleiomyomatosis
Lymphedema
945
MASA
syndrome
McKusick-Kaufman
syndrome
969
Melnick-Needles
syndrome
982
Meningococcal
disease
Mephenytoin
poor metabolizer
Metachromatic
leukodystrophy
Metaphyseal
chondrodysplasia
Methemoglobinemia
1001
1002
Mevalonicaciduria
Microcephaly
Micropenis
Microphthalmia
Muckle-Wells
syndrome
Mucopolysaccharidosis
Mycobacterial
infection
Myelokathexis,
isolated
1050
Myeloproliferative
disorder
Nemaline
myopathy
1080
Nephrolithiasis
Nephronophthisis
1090
Neurodegeneration
Nonaka
myopathy
Norum
disease
1119
Ocular
albinism
1133
Odontohypophosphatasia
Opremazole
poor metabolizer
Orofacial cleft
Osteolysis
Osteopoikilosis
Otopalatodigital
syndrome
Ovarioleukodystrophy
Pachyonychia
congenita
Paget
disease
Pallister-Hall
syndrome
Palmoplantar
keratoderma
Pancreatitis
Papillon-Lefevre
syndrome
Pelger-Huet
anomaly
Periodontitis
Phenylketonuria
1227 Plasminogendeficiency
1238
Polydactyly
Popliteal
pterygium
syndrome
Porphyria
Precocious
puberty,
male
Premature
ovarian
failure
1265
Proguanil
poor metabolizer
Proteinuria
Pseudohermaphroditism,
male
Psoraisis
Pulmonary
fibrosis
RAPADILINO
syndrome
Rapp-Hodgkin
syndrome
Red hair/
fair skin
Refsum
disease
Resting
heart
rate
Restrictive
dermopathy,
lethal
1325
1335
Rothmund-Thomson
syndrome
Salla
disease
Sarcoidosis
Schindler
disease
1361
Senior-Loken
syndrome
1376
Septooptic
dysplasia
Sex
reversal
Short
stature
Sialidosis
Sialuria
Sickle
cell
anemia
Situs
ambiguus
Smith-Fineman-Myers
syndrome
Smith-McCort
dysplasia
Sotos
syndrome
Spina
bifida
Split-hand/foot
malformation
Spondylometaphyseal
dysplasia
1438
Startle
disease
STAT1
deficiency
Steatocystoma
multiplex
1446
Surfactant
deficiency
Sutherland-Haan
syndrome-like
1466
Symphalangism,
proximal
Synostoses
syndrome
Synpolydactyly
Tall
stature
1475
Tay-Sachs
disease
Thalassemias
Thymine-uraciluria
Tolbutamide
poor
metabolizer
1519
Trichodontoosseous
syndrome
Trichothiodystrophy
1526
Tropical
calcific
pancreatitis
Tuberculosis
Tuberous
sclerosis
Twinning,
dizygotic
1542
UV-induced
skin damage
Velocardiofacial
syndrome
Virilization
1565
1580
Weaver
syndrome
Weyers
acrodental
dysostosis
WHIM
syndrome
Wolfram
syndrome
Wolman
disease
Xeroderma
pigmentosum
1611
Yellow
nail
syndrome
Zellweger
syndrome
Adrenocortical
insufficiency
Chondrodysplasia,
Grebe
type
2327
Combined
hyperlipemia
2354
Diabetes
insipidus
3037
3144
Ovarian
dysgenesis
3260
van_der_Woude
syndrome
Basal
ganglia
disease
4291
5170
Pituitary
hormone
deficiency
Renal
hypoplasia,
isolated
Ovarian
sex cord
tumors
Combined
SAP deficiency
Multiple
myeloma
SERPINA3
ACTN3
ADRB1
NR0B1
ALAD
ALB
ABCD1
ALPL
ATP2A2
ATRX
AVPR2
FOXL2
BTK
RUNX2KRIT1
CETP
CTSC
CFTR
CLCN5
COL4A4
COL6A1
COL6A2
COL6A3
COL10A1
CPOX
CTH
CYP2C19
CYP2C9
CYP2D6
CYP11B1
CYP11B2
CYP19A1
CYP21A2
DKC1
DLX3
DNAH5
DPYD
DRD5
ERCC2
ERCC3
ERCC5
ERCC6
EVC
EWSR1
EXT1
F2
F9
FH
FOXC2
FLNA
FLT4
FSHR
FTL
NR5A1
FUT2OPN1MW
GHR
GLB1
GLI3
GLRA1
GNRHR
GP1BB
HADHA
HBA1
HBA2
HBB
HEXA
HFE
HLA-B
HOXA1
HOXA13
HOXD13
HP
HPRT1
HSPG2
IFNG
IFNGR1
IHH
IRF6
KNG1
KRT16
KRT17
L1CAM
LBR
LCAT
LHCGR
LIG4
LIPA
LPL
MAT1A
MBL2
MC1R
MCM6
MTHFD1
MTR MTRR MVK
NAGA
NPHP1
ROR2
OCRL
PAH
PAX2
PDGFRB
PEX1
PEX7
PEX10
PEX13
ABCB4
PLG
POLG
POR
PPT1
PSAP
PTHR1
PXMP3
PEX5
OPN1LW
RMRP
SFTPC
SHOX
SLC3A1
SOX9
SPINK1
STAT1
TBX1
TBCE
TERC
TF
TITF1
TPM2
TSC1TSC2
UMOD
WFS1
CXCR4
FGF23
MKKS
GDF5
TP73L
DNAH11
TNFRSF11A
HESX1
EIF2B4
EIF2B2
EIF2B5
NOG
RECQL4
GNE
ENAM
ZMPSTE24
LEMD3
SLC17A5
DNAI1
SAR1B
SLC45A2
UGT1A1
DYM
BCOR
PEX26
HR
CFC1
ANKH
CARD15
NSD1
VKORC1
MCPH1
PANK2
CIAS1
ANTXR2
NPHP4
The human disease network
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Supporting Information Figure 13 | Bipartite-graph representation of the diseasome. A disorder (circle) and a gene (rectangle) are connected if the gene is implicated in the disorder. The size of the circle represents the number of distinct genes associated with the disorder. Isolated disorders (disorders having no links to other disorders) are not shown. Also, only genes connecting disorders are shown.
Disorder Class
Disorder Name
Bone
Cancer
Cardiovascular
Connective tissue disorder
Dermatological
Developmental
Ear, Nose, Throat
Endocrine
Gastrointestinal
Hematological
Immunological
Metabolic
Muscular
Neurological
Nutritional
Ophthamological
Psychiatric
Renal
Respiratory
Skeletal
multiple
Unclassified
5233 Placental steroid sulfatase deficiency
5170 Ovarian hyperstimulation syndrome
4291 Cerebral cavernous malformations
3558 Ventricular fibrillation, idiopathic
3512 Total iodide organification defect
3260 Premature chromosome condensation w/ microcephaly, mental retardation
3229 Pigmented adrenocortical disease, primary isolated
3212 Persistent hyperinsulinemic hypoglycemia of infancy
3144 Optic nerve coloboma with renal disease
3037 Multiple cutaneous and uterine leiomyomata
2785 Hypoplastic left heart syndrome
2385 Creatine deficiency syndrome, X-linked
2354 Congenital bilateral absence of vas deferens
2327 Chronic infections, due to opsonin defect
1614 Yemenite deaf-blind hypopigmentation syndrome
1611 XLA and isolated growth hormone deficiency
1586 Weissenbacher-Zweymuller syndrome
1580 Warfarin resistance/sensitivity
1565 Vitamin K-dependent coagulation defect
1555 VATER association with hydrocephalus
1545 Unna-Thost disease, nonepidermolytic
1542 Ullrich congenital muscular dystrophy
1528 Trismus-pseudocomptodactyly syndrome
1526 Trifunctional protein deficiency
1519 Transposition of great arteries, dextro-looped
1518 Transient bullous of the newborn
1490 Thanatophoric dysplasia, types I and II
1476 Tauopathy and respiratory failure
1475 Tarsal-carpal coalition syndrome
1466 Sweat chloride elevation without CF
1456 Subcortical laminar heterotopia
1446 Stevens-Johnson syndrome, carbamazepine-induced
1438 Stapes ankylosis syndrome without symphalangism
1432 Spondylocarpotarsal synostosis syndrome
1414 Solitary median maxillary central incisor
1401 Skin fragility-woolly hair syndrome
1396 Silver spastic paraplegia syndrome
1383 Severe combined immunodeficiency
1376 Sensory ataxic neuropathy, dysarthria, and ophthalmoparesis
1361 Schwartz-Jampel syndrome, type 1
1347 Sandhoff disease, infantile, juvenile, and adult forms
1335 Robinow syndrome, autosomal recessive
1325 Rhizomelic chondrodysplasia punctata
1297 Pyruvate dehydrogenase deficiency
1267 Prolactinoma, hyperparathyroidism, carcinoid syndrome
1265 Progressive external ophthalmoplegia with mitochondrial DNA deletions
1263 Prion disease with protracted course
1239 Pneumothorax, primary spontaneous
1238 Pneumonitis, desquamative interstitial
1232 Pituitary ACTH-secreting adenoma
1229 Pigmented paravenous chorioretinal atrophy
1227 Pigmentation of hair, skin, and eyes, variation in
1183 Papillary serous carcinoma of the peritoneum
1174 Pallidopontonigral degeneration
1164 Osteoporosis-pseudoglioma syndrome
1153 Ossification of the posterior longitudinal spinal ligaments
1140 Oligodontia-colorectal cancer syndrome
1133 Oculofaciocardiodental syndrome
1119 Norwalk virus infection, resistance to
1113 Noncompaction of left ventricular myocardium
1105 Newfoundland rod-cone dystrophy
1104 Nevus, epidermal, epidermolytic hyperkeratotic type
1096 Neurofibromatosis-Noonan syndrome
1090 Neural tube defects, maternal risk of
1080 Nephrogenic syndrome of inappropriate antidiuresis
1057 Myokymia with neonatal epilepsy
1056 Myoglobinuria/hemolysis due to PGK deficiency
1050 Myelomonocytic leukemia, chronic
1016 Mitochondrial complex deficiency
1002 Methylcobalamin deficiency, cblG type
1001 Methionine adenosyltransferase deficiency, autosomal recessive
982 Melorheostosis with osteopoikilosis
969 Medullary cystic kidney disease
959 Mastocytosis with associated hematologic disorder
945 Mandibuloacral dysplasia with type B lipodystrophy
942 Malignant hyperthermia susceptibility
930 Lynch cancer family syndrome II
913 Lower motor neuron disease, progressive, without sensory symptoms
891 Leukoencephalopathy with vanishing white matter
868 Laryngoonychocutaneous syndrome
847 Keratosis palmoplantaria striata
845 Keratoderma, palmoplantar, with deafness
843 Keratitis-ichthyosis-deafness syndrome
833 Juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome
830 Jervell and Lange-Nielsen syndrome
809 Infundibular hypoplasia and hypopituitarism
803 Immunodysregulation, polyendocrinopathy, and enteropathy, X-linked
792 Hystrix-like ichthyosis with deafness
785 Hypoplastic enamel pitting, localized
780 Hypoparathyroidism-retardation-dysmorphism syndrome
734 Hyperkeratotic cutaneous capillary-venous malformations
733 Hyperkalemic periodic paralysis
727 Hyperferritinemia-cataract syndrome
701 Homozygous 2p16 deletion syndrome
699 Homocystinuria-megaloblastic anemia, cbl E type
679 High-molecular-weight kininogen deficiency
665 Hemosiderosis, systemic, due to aceruloplasminemia
646 Hearing loss, low-frequency sensorineural
626 Greig cephalopolysyndactyly syndrome
604 Glutathione synthetase deficiency
594 Glomerulocystic kidney disease, hypoplastic
584 Giant platelet disorder, isolated
558 Fuchs endothelial corneal dystrophy
549 Foveomacular dystrophy, adult-onset, with choroidal neovascularization
545 Focal cortical dysplasia, Taylor balloon cell type
544 Fluorouracil toxicity, sensitivity to
539 Fibular hypoplasia and complex brachydactyly
535 Fibrocalculous pancreatic diabetes
527 Fatty liver, acute, of pregnancy
474 Emery-Dreifuss muscular dystrophy
471 Elite sprint athletic performance
463 Dystransthyretinemic hyperthyroxinemia
461 Dyssegmental dysplasia, Silverman-Handmaker type
453 Dysalbuminemic hyperthyroxinemia
452 Dyggve-Melchior-Clausen disease
441 Dopamine beta-hydroxylase deficiency
439 Dissection of cervical arteries
438 Disordered steroidogenesis, isolated
434 Dilated cardiomyopathy with woolly hair and keratoderma
422 Dermatofibrosarcoma protuberans
418 Dentinogenesis imperfecta, Shields type
396 Cyclic ichthyosis with epidermolytic hyperkeratosis
379 Craniofacial-skeletal-dermatologic dysplasia
378 Craniofacial-deafness-hand syndrome
377 Craniofacial anomalies, empty sella turcica, corneal endothelial changes
357 Conotruncal anomaly face syndrome
347 Colonic aganglionosis, total, with small bowel involvement
344 Cold-induced autoinflammatory syndrome
329 Chylomicronemia syndrome, familial
320 Choreoathetosis, hypothyroidism, and respiratory distress
313 Cholesteryl ester storage disease
294 Cerebrovascular disease, occlusive
292 Cerebrooculofacioskeletal syndrome
287 Central hypoventilation syndrome
279 Cavernous malformations of CNS and retina
275 Carpal tunnel syndrome, familial
217 Bone mineral density variability
210 Blepharophimosis, epicanthus inversus, and ptosis
198 Beta-2-adrenoreceptor agonist, reduced response to
192 Beare-Stevenson cutis gyrata syndrome
182 Bannayan-Riley-Ruvalcaba syndrome
171 Attention-deficit hyperactivity disorder
162 Athabaskan brainstem dysgenesis syndrome
144 Arrhythmogenic right ventricular dysplasia
137 Apparent mineralocorticoid excess, hypertension due to
129 Anxiety-related personality traits
126 Anterior segment anomalies and cataract
117 Angiotensin I-converting enzyme
107 Analgesia from kappa-opioid receptor agonist, female-specific
96 Alternating hemiplegia of childhood
92 Alpha-thalassemia/mental retardation syndrome
87 Alpha-1-antichymotrypsin deficiency
77 Aldosterone to renin ratio raised
53 Adrenal hyperplasia, congenital
26 Achondrogenesis-hypochondrogenesis, type II
18 Acampomelic campolelic dysplasia
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possible causal link between HBP and early mortality. Moreover, the age stratification 
criterion does not distinguish between younger and older adults. A recent review 
suggests this may overshadow the role of DBP in younger adults (less than 40 years of 
age) where high DBP predominates and the risk of death rising sharply with DBP values 
above 90 mm Hg [64, 66, 67]. Furthermore, ambulatory DBP and SBP measurements as 
a mortality predictors in young Japanese decreased the number of stroke or CV-related 
deaths, while a decreased nocturnal decline in SBP was associated with a higher risk of 
CV mortality and morbidity [68, 69]. In other words, people under 40 years of age may 
possibly be at  high risk from early mortality  due to HBP, either DBP, SBP or even both, 
which is not currently reflected in the early mortality age-classification criteria.
2.6.2.CHOLESTEROL
In 2010, Statistics Canada, following the Canadian Health Measures Survey, declared 
that over 40% and 25% of Canadians, between 20 and 79 years of age, had unhealthy 
levels of total CHOL and triglycerides (TG), respectively (Figure 5) [70].
DLP or dysregulation of the blood lipid levels has been recognized as major risk factors 
for CVD [71, 72]. Abnormally high levels of CHOL (>5.2 mmol/L for ages between 20 
and 79), low density lipoproteins CHOL (LDL-c >3.36 mmol/L) and TG (>1.7 mmol/L), 
combined with low high density lipoproteins CHOL (HDL-c <1.3 mmol/L) elevate the 
risk for CHD [53, 70, 73-75]. Moreover, high blood CHOL, TG and LDL-c levels are 
also important risk factors for cerebrovascular diseases (CBVD) [76]. Inversely, high 
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plasma levels of HDL-c decreases independently  and strongly  the incidence of CVD and 
CHD mortality [77-79].
Figure 5. Canadian adults with unhealthy levels of HDL-c, LDL-c, TG and total 
CHOL, by age groups (from 20 to 79 years). All data presented are from fasting respondents 
and do not account for the impact of lipid adjusting therapy. Original data sources from the Canadian 
Health Measures Survey, 2007 to 2009 [70].
2.6.3.AGE AND SEX
Aging can be defined as a series of morphological and functional variations happening 
over time [80]. After an organism reaches its maximal reproductive potential, the 
deterioration of the biological functions begins. In fact, the risk of mortality  and 
morbidity from CVD, such as atrial fibrillation, atherosclerosis, stoke, MI and HF, 
increases with age [81-86]. Nevertheless, CVD are sex-specific traits [18, 87]. In the 
Framingham Heart Study, men’s incidence doubles with age for MI while it quintuples 
in women from the age groups of 55-65 to 85-94 [83, 86, 88]. In pathophysiological 
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states, heart aging can be caused by cardiomyocytes apoptosis stimulation, which can 
lead to poor LV remodeling and eventually HF [83].
2.7. SYNAPTIC PLASTICITY IN CVD
Stress and consumption of psychoactive substances, e.g. tobacco, coffee and alcohol is 
common and even encouraged in today world [89, 90]. Both stress and substance usage are 
involved in obesity and CVD [91]. Because all these traits arise from a multifactorial genetic 
and environmental background, we were not surprised to find common genes shared in the 
neural synapse to obesity, stress, substance use and CVD in the SLSJ population [92]. A 
significant number of genomic determinants overlapped for stress, obesity, substance use, 
heart rate and BP. This finding suggests that common pathways of synaptic plasticity with 
genetic variations underlie these traits. From this, we can assume that the subjects’ lifestyle 
and/or habits can be affected by  interactions from the synapses’ genetic background. In turn, 
this lifestyle will alter body systems (e.g. CV system) which will modify the CV outcome and 
risk factors. This suggests that synaptic plasticity plays a predominant role in complex 
multifactorial disorders affected by lifestyle (Figure 6) [93]. In addition, these new findings 
are supported by  the growing awareness of the “human disease network”, which depicts 
interconnectivity of the complex disorders (e.g. CVD; Figure 3) [26]. For future perspectives, 
this will be a crucial analysis of outcomes in subjects with an increased response to stress vs. 
those who did not.
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Figure 6. Hypothetical model of the interaction between stress, synaptic plasticity, 
substance us, obesity and related CV outcomes. Original picture from Nikpay, et al. [92].
2.8. PROJECT DESCRIPTION
Previous genealogical research on the geographically isolated population of French-Canadians 
from the SLSJ region provided the most detailed genome-wide set of highly-significant 
qualitative and quantitative linkage loci of hypertension and related traits [1, 2, 18]. Our 
samples comprises of 120 hypertensive and dyslipidemic families. These findings also showed 
that the degree of genetic homogeneity increased by selecting families with a high prevalence 
of HBP. As such, we decided to characterize in the current study  the families at high-risk for 
CVD. Some were classified as having a higher risk of early  death and, others, at lower risk 
[13]. We propose here a multistep  project to analyze the fatal and non-fatal outcomes of these 
French-Canadian families.
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Since we have already obtained the informed consent of participants who enrolled in the study, 
the first  step was to characterize the subsequent  morbidity status, after which,  treating 
physician charts and hospital records were reviewed. In fact, we examined their ways of living 
by looking at their medical history. The diseases were classified according to the International 
Classification of Disease (ICD) and will be grouped into fatal and non-fatal outcomes (FO and 
NFO, respectively). The grouping of different category of events, e.g. CV events, will be 
discussed in Chapter II: Methods. Adjudication and ascertainment procedure were conducted 
by an archivist, family physician and internist, with a specialty in cardiology (i.e. the 
Adjudication committee).
2.9. HYPOTHESIS
We hypothesize that our sample will demonstrate distinct characteristics in the prevalence of 
diseases with FO and NFO, especially  in relation to CV cause, from general population. In the 
future, further analysis will include differences between subjects with or without obesity, with 
high or low body water and with low or high response to stress or insulin resistance.
2.10. OBJECTIVE
In order to appreciate the clinical relevance, we want to describe and study  diseases in subjects 
with FO and compare them to subjects with NFO. In turn, this will lead to studying families 
and their respective members in relation to their risk of early mortality. This will also be 
achieved by comparing their phenotypic characteristics gathered here. In summary, by 
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examining the non-deadly outcomes of French Canadian families, we want to describe our 
sample population through the differences between FO and NFO at a clinical level.
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CHAPTER III:
Methods
48
Methods
3.
3.1. ETHICS AND ACCESS TO INFORMATION BOARDS
The Research Ethics Committees of the Centre de santé et de services sociaux de Chicoutimi, 
l’Université du Québec à Chicoutimi, and the Centre Hospitalier de l’Université de Montréal, 
reviewed and approved this study. The written consents of all subjects participating were 
obtained before the data collections begun. The families and their extensive phenotyping were 
described previously in detail [1, 17, 18]. Among the numerous phenotypes monitored in this 
cohort, those that are investigated in this study are described below.
In order to obtain the causes of death of proband’s family members, we have written and 
submitted an authorization request to the Commission d’accès à l’information du Québec 
(CAIQ; Quebec’s access to information board) in July 2011. However, we are still awaiting 
their approval concerning this matter. Once we have obtained this, we will be able to receive 
from the ISQ the causes of death for those members and to proceed with the analysis of the 
families displaying early mortality  and look at the possible relation with CVD and FO (Figure 
7).
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Figure 7. Flowchart depicting the multi-step procedure in retrieval and validation of the data on dates 
and causes of death. CAIQ: Quebec’s access to information board; CHUM: Centre Hospitalier de 
l’Universite de Montreal; CHS: Complexe Hospitalier de la Sagamie; MSSS: Québec Ministry of 
Health; ISQ: Québec Institute of Statistics. 
Figure 7. Fl wch rt depicting the multi-step procedure in retrieval and validation of the 
data and causes of d th. CAIQ: Quebec’s access to information board; CHUM: Centre Hospitalier de 
l’Universite de Montreal; CHS: Complexe Hospitalier de la Sagamie; MSSS: Québec Ministry of Health; ISQ: 
Québec Institute of Statistics.  Reference: Dr. Pavel Hamet’s “Search for genes of hypertension” grant application; 
Figure 7, by permission.
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3.2. FAMILY COHORT
Extensive studies have been done on the population, i.e. analysis of founder effect, heritability 
estimates, genetic analyses including linkage and association and comparison between sex 
differences in the field of CVD, especially HBP, and associated metabolic components [1, 2, 
14-18, 92, 94-100]. The probands for this study were recruited from relatively genetically 
differentiated families in the SLSJ area of the Canadian province of Quebec [1].
The families were ascertained by the presence of at least one sibpair with HBP and DLP. 
Sibship sizes ranged from 2 to 11 persons (mean 3.9; median 3). The affected sib pair–
inclusion criteria were essential hypertension (SBP > 140 mmHg and/or DBP > 90 mmHg on 
two occasions or the use of antihypertensive medication), DLP (plasma CHOL 5.2 mmol/L 
and/or HDL-c 0.9 mmol/L or the use of lipid lowering medication), BMI < 35 kg/m2 , age 18–
55 years, and Catholic French Canadian origin. Exclusion criteria included secondary 
hypertension, DBP > 110 mmHg in spite of the use of medication, DM, renal or liver 
dysfunction, malignancy, pregnancy, and substance abuse. Once the affected sib pairs were 
selected, all first and second-degree relatives aged > 18 years were invited to participate in the 
study, independent of health status. The recruited population included 120 families (mean size 
7.3 persons; median size 5 persons), comprising 897 subjects and 1,617 sib pairs (259 
concordant-affected, 556 discordant, and 802 non-affected sib pairs) [1, 2, 18].
The SLSJ population is subjected to a founder effect that reflects its demographic history: it 
was shaped by its very  early founders, starting in 1675 in the Charlevoix settlement, followed 
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by migration to the SLSJ region [1]. Since 1870, the migration rates were relatively low and 
the population has grown from 5,200 in 1852 to 286,649 in 1996 mostly due to the very large 
family sizes in each generation; after which year, this population isolate started to decline to 
278,279 in 2001 and furthermore to 272,610 individuals in 2006 [17, 101, 102].
In gene finding studies, the founder effect observed in this region provides many advantages, 
such as lower allelic and locus heterogeneity  (key features common in complex diseases that 
obscure association signals), environmental stratification and population stratification 
likelihood compared to general populations.
3.3. PHENOTYPING
All phenotyping was performed by trained personnel who followed standard operating 
procedures [1, 14-17]. In summary, 294 subjects without any  contraindications were invited 
for extensive phenotyping. Their antihypertensive drugs were withdrawn for 1 week and lipid-
lowering agents for 1 month. The full phenotyping was performed in a group  of 159 
normotensive and 135 hypertensive subjects [1, 17, 18]. The data on the current generations in 
our database comprise over 50,000 SNPs (single nucleotide polymorphisms), 450 
microsatellites, 539 direct and derived phenotypes, history and pedigree on 16 family 
generations thanks to the BALSAC project, medical status and diagnostic for most family 
members and DNA samples [1, 14-18].
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3.4. PRELIMINARY OVERVIEW OF DATA ORGANIZATIONS
In this Chapter, the data gathered from participating subjects will be presented and explained 
for better understanding of the undertaken study. First, all the data have been divided into to 
two main categories: (1) FO and (2) NFO (Figure 8).
FO NFO
DATA
Figure 8. Main data organization from the subjects of the SLSJ region during the 
present study.
Following this first division, each of the categories was sub-divided into three categories: (1) 
CVD, (2) non CV diseases and (3) other disorders (Figure 9).
FO
CVD Non CV Other
   
NFO
CVD Non CV Other
Figure 9. Organization of sub-categories in which the data gathered from the subjects of 
the SLSJ region has been classified.
Within each of the six subcategories, the divisions became more specific according to their 
risk and relation to CVD. The more detailed composition of each of them will be shown in 
section “Data Compilation” of this Chapter.
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3.5. SUBJECTS STUDIED
Here, we will try  to explain as clearly as possible the differences between the participating and 
analyzed subjects in this study [1]. All Chicoutimi subject’s have received care at the Centre 
de santé et des services sociaux de Chicoutimi where the data were gathered for more than 3 
months. Together, a total of 896 subjects have participated in the initial study. However, 
several factors have influenced the final number of subjects that are actually  presented in this 
thesis (Figure 10).
Figure 10. Summary of the subjects’ recruitment.
3.5.1.CONSENT
Each participating subject  has given their consent to participate in the initial study. 
However, not all participant wanted their data to be used in sub-sequent studies. The 
!
All!subjects!Geographical!location!Consenting!Collected!Status!
• 846!subjects!• Chicoutimi!• 604!subjects!• 567!subjects!
• 380!subjects!• 343!living!• 37!deceased!
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following table depicts this information (Table IV). In summary, 567 subject could be 
analyzed immediately  at the time of data gathering but, due to other limiting factors (e.g. 
requirement for re-consenting, CAIQ etc.), 380 were analyzed at the time of the writing 
of this thesis.
Table IV. Representation of the consent status from the participating subjects. Other 
category refers to consents that remain to be found (n=65) and subjects from Chicoutimi living in Montreal 
(n=227) that remain to be gathered. Note: n = number of subject.
Consent status n
Consenting subjects from Chicoutimi 567
Non-consenting subjects from Chicoutimi 37
Other 292
Total 896
3.5.2.DATA SOURCES FOR THE PRESENT STUDY
In order to ascertain subjects’ diagnosis and outcomes, we have examined each of their 
medical chart and hospital records at Centre de santé et des services sociaux de 
Chicoutimi, the largest  in the SLSJ region (http://www.csss-chicoutimi.qc.ca). A total of 
380 subjects were examined and their medical history pertaining to the mortality risk 
was recorded. All of these subjects have received their care at the site aforementioned. 
During the data gathering, it is to be noted that 26 subjects were hospitalized and their 
charts unavailable at that time. They will be analyzed in the future. To comply with the 
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ethic committee approval, there was no direct  contact with subjects, only  their hospital 
or clinic charts were examined.
In addition, 121 patients of the 380 have been seen in a specialized clinic, Lipid Clinic 
(Clinique des Lipides), of the Centre de santé et des services sociaux de Chicoutimi. 
This helped improve the selection and information for those 121 subjects since more in 
depth testing and questioning was performed on these subjects. In other words, it helped 
confirm some diagnosis (e.g. hypertension, type of DLP, DM, etc.) and even 
‘diagnosing’ (in terms of data collecting) a disease for a given subject. For example, 
Subject B had two charts (1 at the Hospital, 1 at the Clinic). The hospital chart showed 
lab results suggesting type 2 diabetes (T2D) diagnosis (high fasting glucose) but no 
physician ‘official’ mention (see criteria in Table XVII). On the other side, the clinic 
chart for the same patient gave the information that  a physician had in fact diagnosed 
T2D following appropriate testing.
3.6. DIAGNOSIS ASCERTAINMENT AND CLASSIFICATION
Dr. Milenko Petrovich, an Internist with a special background in cardiology was consulted 
during this study and ascertained all diagnostic findings. For the purpose of this study, the 
consulting specialist  has examined in depth each patient’s diagnosis (and undiagnosed 
diseases) in order to confirm the data and check for false positive or negative results for this 
study (e.g. misdiagnosis of DM with documented laboratories meeting criteria or undiagnosed 
CVD). This will be discussed more in length in the “Discussion” Chapter.
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The definitions used to classify  the diseases in their respective categories are discussed in the 
following sections. They were chosen after lengthy discussion with the Adjudication 
Committee in order to have as much as possible an objective system to stratify  the subjects. 
The dichotomous distinction of diagnosis into FO and NFO is based on the potential severity 
of the diseases in relation to their risk of mortality  (Figure 11). Here, we will explain our 
reasoning while the limitations themselves will be discussed later in the Discussion Chapter.
FO are high-risk diseases, which could put at risk for mortality and serious complications. 
NFO are low-risk conditions, which usually do not result in death or serious complications. 
Following this train of thought, we have decided to further subdivide the seriousness of the 
diseases from the circulatory  system by using the Major Adverse Cerebral and/or 
Cardiovascular Event (MACCE) score (discussed in Section 3.18; Table XV). In summary, the 
advantages of this novel grading systems are (1) that it was adapted to include CBVD and (2) 
measured the degree of severity.
For example, lets discuss the case of first  degree AV block. This pathology has been associated 
in both healthy patients and those with underlying CHD with a higher risk of morbidity  and 
mortality [173, 174]. In most situations, it is benign and is attributed a MACCE score of 1/4. 
Nevertheless, in rare situations, a patient can develop a high-grade first degree AV block. 
Being potentially deadly, this is a recommendation for a pacemaker and would be classified as 
MACCE 3/4 [174].
57
Another example is sinus bradycardia. In the great majority of cases, it is also a benign 
condition, which can be caused by medication or physiological consequence of training [175]. 
However, in some situations, low cardiac output and symptomatic hypotension can cause sinus 
bradycardia to be potentially deadly, which absolutely requires permanent pacemaker 
implantation. This situation is relatively frequent in clinical practice. Thus, FO (high-risk 
diseases) have in addition the MACCE scoring while NFO (or with low-risk) do not.
3.7. DEFINING DIAGNOSIS AND OUTCOMES
In this present analysis, we made a distinction between a diagnosis and an outcome. 
Diagnosis comprise all the health events that have occurred to the subject before the current 
analysis but since enrolling in the study, i.e. over the last 11 years.
Outcomes we define an ‘outcome’ as an event with high risk of morbidity  that  has occurred to 
a given subject after the time (year) he/she entered the study. Note: for a known and 
documented outcome without a specific date, the year of the patient’s enrollment will be taken 
into account (e.g. as if the outcome occurred right after his/hers enrollment).
First outcome is the term used to define the very  first event that affected the subject following 
his/her enrollment. 
58
Here is an example of a subject’s medical history  (Figure 11). Subject A enrolled in the study 
in 1995 and has suffered from three events: the first in 1980, the second in 1995 and the third 
in 2010; this patient had three diagnosis (1980) but only  two of them are considered outcomes 
(1995 and 2010). In this case the first outcome would be in 1995.
Diagnosis:
3
(1980, 1995, 
2010)
Outcomes:
2
(1995, 2010)
Subject A (enrolled in 1995):
3 occurred events (1980, 1995, 2010)
Figure 11. Schematic explanation of the medical history classification in outcomes and 
diagnosis for hypothetical Subject A.
3.8. FIRST STAGE: SUBJECT IDENTIFICATION
A total of 380 subjects were examined through their medical records at the Hospital or Lipid 
Clinic at the Centre de santé et des services sociaux de Chicoutimi. In the following figure, we 
will show the basic information ascertained for each subject’s identification and medical 
history in cases of both fatal and non-fatal outcomes (Figure 12). This pertains to the subject’s 
identification and global affections related to DM and HBP. More detailed information about 
each criteria and ICD used will be discussed later in this Chapter.
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!!!! !!
!
Subject!ID!
Gender!
Date!of!birth!
Date!of!death!Lifespan!
Research!ID!
Lipid!clinic! • Did!the!subject!have!a!chart?!• Did!he!have!an!angiography?!
HTN! • Treated!or!untreated?!• New!onset?!(Year)!• Earliest!and!latest:!SBP!and!DBP!measured!• Pulse!rate!
DM! • Type?!(PreKDM,!T1D,!T2D)!• Treated!or!untreated?!• New!onset?!(Year)!
!!!! !!
!
Subject!ID!
Gender!
Date!of!birth!
Date!of!death!Lifespan!
Research!ID!
Lipid!clinic! • Did!the!subject!have!a!chart?!• Did!he!have!an!angiography?!
HTN! • Treated!or!untreated?!• New!onset?!(Year)!• Earliest!and!latest:!SBP!and!DBP!measured!• Pulse!rate!
DM! • Type?!(PreKDM,!T1D,!T2D)!• Treated!or!untreated?!• New!onset?!(Year)!
Figures 12. Subjects’ primary data used for identification and analysis of FO and NFO. 
Note: date of death was only given when appropriate. ID=Identification
3.9. SECOND STAGE: FATAL OUTCOMES
As previously mentioned, the morbidity and mortality data gathered comprise common data 
designs, e.g. for living and deceased subjects. The following figure depicts the diagnosis 
organization for CV FO (Figure 13).
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Figure 13. Second stage: FO of the circulatory system. It is to be noted that renal failure from CV 
origin has also been classified in this category, under “Hypertensive diseases - other”.
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Each of the sub-categories of Figure 12 encompasses different diseases, which will be detailed 
in the section “Data compilations” of this Chapter. The following figures depict the FO 
organization for non-CV origin and all other causes (Figures 14 and 15, respectively).
FO of non-CV origin
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Pre-DM
DM
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Figure 14. Second stage: FO of non-CV origin.
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Figure 15. Second stage: FO from all other causes.
3.10. THIRD STAGE: NON-FATAL OUTCOMES
As previously mentioned, the morbidity and mortality data gathered comprise common data 
designs, e.g. for living and deceased subjects. The following figure depicts the organization of 
NFO from the circulatory  system, as well as non-CV and all other causes (Figure 16, 17 and 
18, respectively).
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Figure 16. Third stage: NFO of the circulatory system.
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Figure 17. Third stage: NFO of non-CV origin.
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Figure 18. Third stage: NFO from all other causes.
3.11. FOURTH STAGE: SUPPORTING INFORMATION FOR FATAL OUTCOMES
In order to assess a subject’s state or FO, i.e. for the morbidity  and mortality causes, a rigorous 
and consistent documentation sources have to be observed. All diagnostics and causes of death 
have been documented according to the available proof in the subject’s medical records (Table 
V). In case of contradiction between diagnostic and medical test results, the consulting 
internist on the research project  decided the final marked diagnostics. For example, diagnosed 
angina with normal stress test and angiography is dismissed according to the specific tests 
done to the patient.
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Table V. Supporting documentation for FO.
Outcomes Supporting documentation (if available)
Non-fatal stroke Clinical notes (e.g. Discharge summary)
CT report
MRI report
Any other relevant documentation
Non-fatal myocardial 
infarction
Clinical notes (e.g. Discharge or admission summary)
Laboratory reports of biochemical markers of myocardial Injury 
(e.g. Creatine kinase and/or troponins)
ECG reports
Any other relevant documentation
Death Clinical notes
Death certificate
Autopsy report
Any documentation supporting the diagnosis if autopsy not 
performed
Any other relevant documentation
New or worsening 
nephropathy
Clinical notes
Laboratory reports of urinalysis
Note: Microalbuminuria must be confirmed on two separate 
specimens.
Laboratory reports clearly indicating the change in serum creatinine 
during study follow-up.
New or worsening eye disease Ophthalmologist or other report, which may include reference to:
 Retinal photographs
 Fundoscopy
 Visual acuity
 Any other relevant documentation
Fatal accidents caused by 
cardiovascular defects
 Autopsy report
 Death certificate
 Medical history records
 Discussion with physicians 
3.12. FOURTH STAGE: SUPPORTING INFORMATION FOR DIAGNOSIS
Diagnosis recorded were supported, when possible, with laboratories and specialized medical 
tests (Table VI). This information was referred to by the Adjudication Committee when 
discussion about subjects’ diagnosis. The specialist, also, used this information in order to 
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confirm each diagnosis or not. It is to be noted that not all the following information was 
available systematically for each patient. Nevertheless, depending on the subject’s affection, 
these were usually enough to support the diagnosis.
Table VI. Fourth stage: supporting information for diagnosis of FO and NFO.
Clinical exams and questioning
Personal Habits Anthropometric data
Smoking Weight (kg)
Degree of physical activity Height (cm)
Drinking status (alcohol use) BMI (kg/(cm2))
Drug abuse Body composition
Medications Abdominal circumference
Laboratories
Blood sugar level (random, fasting, etc.) Iron profile (TIBC, iron, ferritin, transferrin)
Coagulogram (PT (INR), PTT, bleeding time, 
fibrinogen)
Liver profile (e.g. AST, ALT, GGT, bilirubin, 
alkaline phosphatase, LDH)
Cardiac profile (CK, CK-MB, TnI, TnT) CBC (leucocytes, erythrocytes, hemoglobin, 
hematocrit, etc.)
Renal profile (BUN, creatinine, eGFR, 
urinalysis, electrolytes—Na+, K+, Cl- and 
bicarbonates)
Lipid profile (e.g. total CHOL, HDL-c, LDL-c, 
TG, CHOL/HDL ratio)
TSH Albumin (g/L)
Globulin (g/L) Total proteins (g/L)
A.C.E. antigen Oxygen saturation
Other labs
Specific Medical Exam
Resting ECG ECHO
Exercise tolerance (STRESS) test Holter monitoring
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Clinical exams and questioning
Radionuclide myocardial perfusion imaging 
(exercise and dipyridamole)
Coronary angiography
Other angiography Arterial and venous Doppler 
Left ventricular catheterization, ventriculography and selective coronary angiography
All other relevant reports (e.g. lung X-rays, CT scan, MRI, etc.)
A.C.E.=Angiotensin converting enzyme  ALT=Alanine amino-transaminase
AST=Aspartate amino-transaminase  BUN=Blood urea nitrogen
CBC=Complete blood count   CK=Creatinine kinase
CK-MB=Creatinine kinase myoglobin band  CT=Computerized tomography
ECG=Electrocardiogram    ECHO=Echocardiogram
eGFR=Estimated glomerular filtration rate  GGT=Glutamine amino-transaminase
INR=International normalized ratio   LDH=Lactic dehydrogenase
MRI=Magnetic resonance imaging   PT=Prothrombin time
PTT=Partial thromboplastin time   TIBC=Total iron binding capacity
TnI=Troponin I     TnT=Troponin T
3.13. DATA COMPILATIONS
Bearing in mind the basic overview of the six subcategories (Figure 9) and the data sections 
for FO and NFO (Figures 13 to 18), we decided on the following design for the data 
compilations for all subjects. As such, we show in the following tables how our complex data 
were finally organized and classified (Table VII to XII). After this strategic approach, each 
sub-group  was organized following the WHO’s ICD 10 (www.who.org; ICD will be discussed 
later in this Chapter). Note: Tables correspond to their respective figures (i.e. Table VII and 
Figure 13; VIII and 14; IX and 15; X and 16; XI and 17; XII and 18).
Table VII. Classification of the circulatory system FO. MACCE score is adjusted if necessary for 
each patient. ICD10 coding is also specified individually for each disease.
FO of the circulatory system ICD MACCE
Rhythm 
pathologies
Atrial Bradycardia Sinus or atrial R00.1 1-3
Sinus 
pathologies
Pauses <3 seconds long I45.5 1
Pauses >3 seconds long I45.5 2
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FO of the circulatory system ICD MACCE
Rhythm 
pathologies
CHD
Atrial
Sinus 
pathologies
Sinus arrest I45.5 3
Sick sinus syndrome I49.5 2
Non sinus 
pathologies
Fibrillation and flutter
(with CHADS 2)
I48 1
Multifocal atrial rhythm 
AV AV-Bloc 1’ I44.0 1-3
AV-Bloc 2’ Wenckebach 
(Mobitz 1)
I44.1 1
Mobitz 2 I44.1 3
High grade 2’ block I44.1 3
AV-Bloc 3’ Complete I44.2 3
AV dissociation I45.8 3
Accessory 
pathway
I45.6 1
PSVT I47.1 1
Ventricular Left bundle 
branch block
I44.7 3
Ventricular 
tachycardia
Non-sustained I47.2 3
Sustained I47.2 3
Torsade de points I47.2 3
Ventricular 
flutter
I49.0 3
Ventricular 
fibrillation 
I49.0 3
Cardiac arrest I46 3
Other Electromechanical dissociation R94.3
Diagnosis and outcomes
Subjects
First outcome (/%)
Angina Unstable 
angina
Angina:
- crescendo
- de novo effort
- worsening effort
I20.0 3
Intermediate coronary syndrome
Pre-infarction syndrome and 
post-MI
Angina pectoris 
with 
documented 
spasm
Angina:
- angiospastic
- Prinzmetal
- spasm-induced
- variant
I20.1 3
Other forms of 
angina pectoris
Angina of effort I20.8 3
Stenocardia
Angina 
pectoris, 
unspecified
Angina:
-non otherwise specified
-cardiac
I20.9 0-3
Anginal syndrome
Ischeamic chest pain
MI Transmural Anterior wall I21.0 3
Inferior wall I21.1 3
Other sites I21.2 3
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FO of the circulatory system ICD MACCE
HF
(cardiac 
insufficiency)
Valvulopathies 
(non-rheumatic 
valve disorders)
MI
Unspecified sites I21.3 3
Sub-endocardial I21.4 3
Unspecified I21.9 3
Old I25.2 3
Multiple MI I21 3
Total MI I21 3
Other CHD I25.9 3
AG Normal Coronary arteries without any 
stenosis
I25.1 1
Mild CAD Stenosis <70% I25.1 2
Single vessel 
disease
One major CAD I25.1 3
Two vessel 
disease
Two major CAD or isolated left 
main CAD
I25.1 3
Three vessel 
disease
All major CAD or right and left 
main CAD
I25.1 3
Terminal CAD Stenosis non amenable to 
CABG or PTCA
I25.1 3
Grafts Bypass grafts’ stenosis I25.1 3
Treatment CABG 2 grafts Z95.1 3
3 grafts Z95.1 3
≥4 grafts Z95.1 3
Unspecified Z95.1 3
PTCA Low risk—No high risk features Z95.5 2
High risk—Multiple stents, long 
lesions, bifurcation lesion
Z95.5 3
Unspecified Z95.5 -
Diagnosis and outcomes
Subjects
First outcome (/%)
LVSD Mild EF 40-49% I50.1 1
Moderate EF 30-39% I50.1 2
Severe EF ≤ 29% I50.1 3
Unspecified I50.1 0
RVSD Mild I50.0 1
Moderate I50.0 2
Severe I50.0 3
LVDD Mild Abnormal relaxation I50.1 1
Moderate Pseudo-normalization I50.1 2
Severe Restricted I50.1 3
Diagnosis and outcomes
Subjects
First outcome (/%)
Ar Mild I35.1 1
Moderate 2
Severe 3
As Mild I35.0 1
Moderate 2
Severe 3
Mr Mild I34.0 1
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FO of the circulatory system ICD MACCE
Morphologic 
abnormalities
Infective and 
inflammatory 
heart disease
Congenital 
defects
All cardiac 
events
Ischeamic
Mr
Moderate
I34.0
2
Severe 3
Unclassified -
Ms Mild I34.2 1
Moderate 2
Severe 3
Unclassified -
Tricuspid 
regurgitation/
stenosis
Mild I36.0,I
36.1
1
Moderate 2
Severe 3
Pulmonary 
stenosis, 
regurgitation or 
congenital 
anomaly
Mild I37.0, 
I37.1, 
Q22.1
1
Moderate 2
Severe 3
Diagnosis and outcomes
Subjects
First outcome (/%)
LVH By ECHO I51.7 2
By ECG 1
RVD and LVD I51.7 3
Other Auricular dilatation, etc. I51.9 1-3
Diagnosis and outcomes
Subjects
First outcome (/%)
Endocarditis I39 3
Myocarditis I40 3
Pericarditis I30.1 3
Other Unspecified, Carditis, Rheumatic fever, etc. I51.8, 
I01
2
Diagnosis and outcomes
Subjects
First outcome (/%)
Q20-
Q28
1, 2, 3
Diagnosis and outcomes
Subjects
First outcome (/%)
Diagnosis and outcomes
Subjects
First outcome (/%)
TIA G45 3
RIND I63.5 3
Stroke 
(Cerebral 
infarction)
Thrombotic infarct I63.3 3
Embolic infarct I63.4 3
Diagnosis and outcomes
Subjects
First outcome (/%)
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FO of the circulatory system ICD MACCE
Intracranial 
hemorrhage 
All CBVD 
events
Diseases of the 
pulmonary 
circulation
All events of 
the pulmonary 
circulation
Vascular 
disease - 
Arterial
Vascular 
disease - 
Venous
All vascular 
disease
Essential 
(primary) 
hypertension
Epidural Chronic I62.1 2
Acute 3
Subarachnoid Chronic I60 2
Acute 3
Intracerebral I61 3
Diagnosis and outcomes
Subjects
First outcome (/%)
Diagnosis and outcomes
Subjects
First outcome (/%)
Embolism Chronic I26 3
Acute 3
Hypertension Mild I27 1
Moderate 2
Severe 3
Vasculitis Without alveolar hemorrhage I77.6 2
With alveolar hemorrhage 3
Diagnosis and outcomes
Subjects
First outcome (/%)
CBVD Atherosclerosis and unspecified hemorrhage I60.9, 
I67.2
3
Thoracic aorta Atherosclerosis (including embolism and 
thrombosis)
I70.0, 
I74.1
3
Aneurism I71.1, 
I71.2
1-3
Dissection I71.0 1-3
Abdominal 
aorta
Atherosclerosis I70.0 3
Aneurism I71.3,I
71.4
1-3
Dissection I71.0 1-3
Renovascular 
disease
Atherosclerosis of renal artery and arterioles I70.1 3
Renal ischemia and infarction N28.0
Intestinal 
vascular 
disease
Mesenteric ischemia and/or necrosis K55.1 1-3
Atherosclerosis I70.8 3
Peripheral 
vascular 
disease
Atherosclerosis and aneurisms of arteries of 
extremities
I70.2,  
I73, 
I74
3
Multiple arterial embolisms and thrombosis
Other peripheral vascular disease (ischemia, etc.)
SVT I80, 
I82
1
DVT 3
Diagnosis and outcomes
Subjects
First outcome (/%)
Controlled I10 1
Uncontrolled 3
Unspecified 0
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FO of the circulatory system ICD MACCE
Essential 
(primary) 
hypertension
Other 
hypertensive 
diseases
All 
hypertensive 
diseases
Mean BP 
measurements
SBP∆ 2.00 -
DBP∆ -6.79 -
Hypertensive heart disease I11 3
Hypertensive renal disease I12 3
Hypertensive heart and renal diseases I13 3
Secondary hypertension I4 3
Diagnosis and outcomes
Subjects
First outcome (/%)
Total Participating ♀ subjects
Participating ♂ subjects
Subjects affected
Subjects with outcomes
Outcomes
First outcome (/%)
Diagnosis
AG=Angiography    Ar=Aortic regurgitation
As=Aortic stenosis    AV=Atrial-ventricular
CAD=Coronary artery disease   CABG=Coronary artery bypass grafting
CHADS 2=Congestive HF, HBP, Age, DM, and Stroke (or prior TIA)
CBVD=Cerebrovascular diseases   DVT=Deep venous thrombosis
EF=Ejection fraction    ECG=Electrocardiogram
ECHO=echocardiogram    EF=Ejection fraction
LVD=Left ventricular dilatation   LVDD=Left ventricular diastolic dysfunction
LVH=Left ventricular hypertrophy   LVSD=Left ventricular systolic dysfunction
Mr=Mitral regurgitation    Ms=Mitral stenosis
PSVT=Paroxystic supra-ventricular tachycardia RIND=Reversible ischemic neurological deficit
RVD=Right ventricular dilation   RVSD=Right ventricular systolic dysfunction
SVT=Superficial venous thrombosis  TIA=Transient ischemia attack
Table VIII. Classification of non-CV FO. ICD10 coding is also specified individually for each disease.
Non-CV FO ICD
Malignant 
neoplasms
Men Lip, oral cavity and pharynx
Digestive organs
Respiratory and intrathoracic organs
Bone and articular cartilage
Skin
Mesothelial and soft tissue
Breast
Male genital organs
Urinary tract
Eye, brain and other parts of CNS
Thyroid and other endocrine glands
Ill-defined, secondary and unspecified sites
C00-C14
C15-C26, D01
C30-C39
C40-C41
C43-C44
C45-C49
C50
C60-C63
C64-C68
C69-C72
C73-C75
C76-C80
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Non-CV FO ICD
Lymphoid, hematopoietic and related tissue
Independent multiple sites
Diagnosis and outcomes
Subjects
First outcome (/%)
Women Lip, oral cavity and pharynx
Digestive organs
Respiratory and intrathoracic organs
Bone and articular cartilage
Skin
Mesothelial and soft tissue
Breast
Female genital organs
Urinary tract
Eye, brain and other parts of CNS
Thyroid and other endocrine glands
Ill-defined, secondary and unspecified sites
Lymphoid, haematopoietic and related tissue
Independent multiple sites
Diagnosis and outcomes
Subjects
First outcome (/%)
All neoplasm 
events
Diagnosis and outcomes
Subjects
First outcome (/%)
Metabolic causes Pre-DM AFG and IFT 
Diagnosis and outcomes
Subjects
First outcome (/%)
DM Type I
Possible Type II
(not confirmed by 
2nd test)
Diet
Oral Rx
Type II Treated with diet
Oral Rx
Insulin Rx
Unspecified Treated with diet
Oral Rx
Insulin Rx
Diagnosis and outcomes
Subjects
First outcome (/%)
C81-C96
C97
C00-C14
C15-C26
C30-C39
C40-C41
C43-C44
C45-C49
C50
C51-C58
C64-C68
C69-C72
C73-C75
C76-C80
C81-C96
C97
E74.3, R73.0
E10
E11
E11
E14
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Non-CV FO ICD
Metabolic 
syndrome
Previously 
undiagnosed
Criteria
Diagnosis
Obesity Underweight BMI<18.00
Normal BMI 18.00-24.99
Overweight BMI 25.00-29.99
Mild BMI 30.00-34.99
Moderate BMI 35.00-39.99
High BMI>40.00
Diagnosis
Abdominal 
circumference
Men Abnormal>94 cm
Average (/cm)
Women Abnormal>80 cm
Average (/cm)
Diagnosis
Lifestyle Smoking
Alcohol
Drugs
Diagnosis
Hypoglycemia
Diagnosis and outcomes
Subjects
First outcome (/%)
Lipid abnormalities PH
FCD
DBL
Heterozygous FH
Homozygous FH
HTG Borderline high
High
Severe
HALP
Unclassified
Diagnosis and outcomes
Subjects
First outcome (/%)
All metabolic 
events
Diagnosis and outcomes
Subjects
First outcome (/%)
Lung diseases COPD
Infection Pneumonia and Influenza
Collagen vascular diseases
E88.81
R62.8
-
E66.9
E66.8
E66.8
E66.8
-
-
-
-
Z72.0
Z72.1
Z72.2
E16.2
E78.0
E78.4
E78.2
E78.0
E78.0
E78.1
E78.1
E78.1
E78.6
E78.8, E78.9
J44
J09-J18
J84.17
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Non-CV FO ICD
Lung diseases
Inflammatory
Asthma
Pneumoconiosis
Cystic fibrosis
Other ARDS, etc.
All lung events Diagnosis and outcomes
Subjects
First outcome (/%)
Kidney disorders Renal failure Pre-renal
Renal
Post-renal
Unspecified Ex
Acute
Chronic
Electrolyte 
abnormalities
Sodium (Na+) High
Low
Potassium (K+) High
Low
Other
All kidney events Diagnosis and outcomes
Subjects
First outcome (/%)
Total Participating ♀ subjects
Participating ♂ subjects
Subjects affected
Subjects with outcomes
Outcomes
First outcome (/%)
Diagnosis
J20-22
J45
J60-J65
E84
J80 [J00-J99]
-
-
-
N19
N17
N18
E87.0
E87.1
E87.5
E78.6
N00-N29
ARDS=Adult respiratory distress syndrome   Rx=Medication
Table IX. Classification of all other FO. ICD10 coding is also specified individually for each disease.
FO from all other causes ICD
Mental and behavioral
Nervous system Alzheimer’s disease, etc.
Digestive system Other (e.g. sub-occlusion/ileum)
Accidents
Other Bleeding, Enterocolitis due to Clostridium difficile, etc.
Unknown
Total Participating ♀ subjects
F00-F99
G00-G99
K00-K93
V01-X59
R69
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FO from all other causes ICD
Participating ♂ subjects
Subjects affected
Subjects with outcomes
Outcomes
First outcome (/%)
Diagnosis
Table X. Classification of NFO from the circulatory system. MACCE score is considered as 1/4 
for all diseases in the category. ICD10 coding is also specified individually for each disease.
NFO of the circulatory system—MACCE 1 ICD
Cardiac 
diseases
Rhythm 
pathologies
Non-rheumatic 
valve disorders
Subtotal Subjects
Diagnosis
Vascular 
diseases
Venous
Subtotal Subjects
Diagnosis
Hypotension
Subtotal Subjects
Diagnosis
Atrial Sinus 
pathologies
Premature depolarization
(ES)
I49.1
Tachycardia I47.1
Arrhythmia I49
Non sinus 
pathologies
Multifocal rhythm I49
Multifocal tachycardia I49
AV Junctional 
tachycardia
I47.1
Junctional 
premature 
contractions
I49.2
Ventricular Premature 
depolarization
(Extrasystole) I49.3
Hemiblock I44.6, 
I45.4
Bundle branch 
block
I44.7
Aortic Sclerosis, calcification and thickening I35.8
Mitral Sclerosis, calcification and thickening I34.8
Prolapse I34.1
Tricuspid Sclerosis, calcification and thickening I36.8
Pulmonary Sclerosis, calcification and thickening I37.8
Varicose veins, Hemorrhoids, etc. I83, 
I84, 
I87.2
Low risk I95
High risk
Unclassified
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NFO of the circulatory system—MACCE 1 ICD
Total Participating ♀ subjects
Participating ♂ subjects
Subjects affected
Diagnosis
Table XI. Classification of non-CV NFO. ICD10 coding is also specified individually for each disease.
Non-CV NFO ICD
Benign neoplasms Men Lip, oral cavity and pharynx
Digestive organs
Respiratory and intrathoracic 
organs
Bone and articular cartilage
Skin
Mesothelial and soft tissue
Breast
Male genital organs
Urinary tract
Eye, brain and other parts of CNS
Thyroid and other endocrine 
glands
Lymphoid, haematopoietic and 
related tissue
Other
Independent multiple sites
Women Lip, oral cavity and pharynx
Digestive organs
Respiratory and intrathoracic 
organs
Bone and articular cartilage
Skin
Mesothelial and soft tissue
Breast
Female genital organs
Urinary tract
Eye, brain and other parts of CNS
Thyroid and other endocrine 
glands
Lymphoid, hematopoietic and 
related tissue
Other
Independent multiple sites
Subtotal Diagnosis
D10, D11
D12, D13
D14, D15
D16
D23
D19-D21
D24
D29
D30
D31-D33
D34, D35
D36
D17, D18, D36
D10, D11
D12, D13
D14, D15
D16
D23
D19-D21
D24
D25-D28
D30
D31-D33
D34, D35
D36
D17, D18, D36
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Non-CV NFO ICD
Lung diseases
Kidney disorders
Total Participating ♀ subjects
Participating ♂ subjects
Subjects affected
Diagnosis
J00-J99
N00-N99
Table XII. Classification of all other NFO. ICD10 coding is also specified individually for each 
disease.
NFO from all other causes ICD
Mental and behavioral Anxiety
Other
Nervous system
Eye and adnexa Cataracts, etc.
Ear and mastoid process
Digestive system
Genitourinary system
Endocrine, nutritional and metabolic Hypothyroidism
Hyperthyroidism
Blood and blood-forming organs and certain disorders 
involving the immune mechanism
Anemia, etc.
Other
Musculoskeletal system and connective tissue
Accidents
Other
Unknown
Total Participating ♀ subjects
Participating ♂ subjects
Subjects affected
Diagnosis
F00-F99
G00-G99
H00-H59
H60-H95
K00-K93
N00-N99
E00-E90
D50-D89
M00-M99
V01-X59
R69
3.14. RESULT CALCULATIONS
In each of the detailed tables for FO and NFO sub-categories, results were organized to show 
(1) the number of events or ‘n’ (e.g. the number of affections for a given diseases), and (2) the 
n subtype percentage (%) compared to all events of the disease type it belongs to (e.g. 
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bradycardia importance in rhythm pathologies, and total percentage (%) of the event’s weight 
in the whole sub-category of diseases: e.g. bradycardia in CV FO). The following table 
explains all the results calculated within each sub-category (Table XIII). Also, each percentage 
for a sub-category is compared to its respectful type, i.e. diagnosis % vs. all diagnosis %, 
outcome % vs. all outcomes %, first outcome % vs. all first outcomes % of each given 
subcategory.
Table XIII. Explanation of the result calculations.
FO of the circulatory system n Subtype % Total %
Rhythm 
pathologies
Cardiac 
diseases
Total
Atrial Bradycardia A != (A/C) × 100 != (A/P) × 100
Sinus pathologies B != (B/C) × 100 != (B/P) × 100
... ...
... ...
Diagnosis C != (C/G) × 100 != (C/N) × 100
Subjects with outcomes D != (D/G) × 100 != (D/N) × 100
Outcomes E != (E/G) × 100 != (E/N) × 100
First outcomes F != (F/G) × 100 != (F/G) × 100
Diagnosis G - != (G/N) × 100
Subjects with outcomes H - != (H/K) × 100
Outcomes I - != (I/L) × 100
First outcomes J - != (J/M) × 100
... ...
Subjects with outcomes K
Outcomes L
First outcome M
Diagnosis N
3.15. RELATIVE RISK
The basis of our relative risk (RR) calculation is a ratio between proportions of cases with a 
positive outcome in two groups [103]:
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 A RR of 1 signifies that there is no difference between the two groups. However, if RR is < 1, 
it means the event is less likely  to occur in the exposed than the control group. Inversely, if RR 
is > 1, the experimental group is more susceptible to develop the disease than the control. We 
used our analyzed subjects as the ‘exposed group’ and compared them to the general 
population of SLSJ, ‘control group’. The data used for the control group has been presented in 
Chapter II from the Agence de la santé et des services sociaux du Saguenay– Lac-Saint-Jean 
[19]. Here is a calculated RR:
!! = !! + ! !!! ! + !! !!!= ! 1,1031,103+ 1,617 !! 3,878+ 22,9943,878 = 2.8100!
 
 
 
 
 
 
where:  a = total CV FO in our probands = 1,103
  b = total non-CV FO in our probands = 1,617
  c = total CV FO in SLSJ = 3,878
  d = total non-CV FO in SLSJ = 22,994
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Lastly, calculations were checked through the Belgium MedCalc Software for statistics and 
significance (http://www.medcalc.org/calc/relative_risk.php). In addition, it calculates a 95% 
confidence interval (CI) and Z statistic (which indicates the outcome’s  relationship to the 
mean in the outcome’s group of values). A P-value was also considered and statistically 
significant if p ≤ 0.05. Here is an example of the same data previously used for RR calculation 
but through the aforementioned program (Figure 19):
       
Relative risk
Exposed group
Number with positive outcome: a= 1103
Number with negative outcome: b= 1617
Control group
Number with positive outcome: c= 3878
Number with negative outcome: d= 22994
    Test   
Results
Relative risk 2.8100
95 % CI 2.6622 to 2.9659
z statistic 37.486
P < 0.0001
The relative risk is the ratio of the proportions of cases having a positive outcome in two groups.
Relative Risk = (a / (a+b)) / (c / (c+d))
Literature
Sheskin DJ (2004) Handbook of parametric and nonparametric statistical procedures. 3rd ed. Boca Raton:
Chapman & Hall /CRC.
Privacy  Contact  Site map
Version 12.5.0 - Last modified: March 29, 2013 
© 1993-2013 MedCalc Software bvba
MedCalc Software, Acacialaan 22, B-8400 Ostend, Belgium
Home Features Download Order Contact us FAQ Citations Manual
Figure 19. RR calculation with the MedCalc Software 2012, by permission.
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3.16. CHI SQUARE TEST
We used the Chi square test (χ2) to validate our results. With the result for χ2, we can obtain 
the p-value by referring to widely  available pre-existing tables (on the Internet or statistical 
books) and identify the corresponding score for the χ2 obtained. The formula is as follows:
!! = ! − ! !! !! !ℎ!"!!!!!! = !ℎ!!!"#$%&!!!!!!!!!!! = !ℎ!!!"#!!"!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! = !"#$%&$'!!"#$!%&'!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! = !!"#!$%!&!!"#$!%&'!
!
This test was used to verify the null hypothesis; the observed data frequencies could be 
predicted from the sample population. In fact, the P-value will answer if the data observe can 
actually generate a large discrepancy between the expected and observed results. Thus, the 
smaller is the P-value, the stronger statistical evidence that the values are not sampled from the 
expected distribution.
The results generate an χ2 value with its degrees of freedom, and states a P-value. It is to be 
noted that the same criteria were applied for the P-value (p ≤ 0.05) as for the RR. We used the 
California’s GraphPad Software founded in 1984 to ascertain calculation for χ2 test (http://
graphpad.com/quickcalcs/chisquared1/). Here is an example of a χ2 result from this program 
(Figure 20):
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AB
Figure 20. χ2 test with the GraphPad Software, by permission. A) Inputing the necessary data; 
B) Results of data inputed in A.
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3.17. INTERNATIONAL CLASSIFICATION OF DISEASES
The FO and NFO were meticulously  categorized following the ICD from the WHO: ICD 
version 9 (ICD9) for ones prior to 2000 and ICD version 10 (ICD10) for those from year 2000 
onwards, depending on data available. However, for the purpose of reporting in this work, we 
converted all available ICD9 coding to ICD10 version using the ICD9-ICD10 Conversion 
Database (http://www.icd10data.com/Convert) and simultaneously consulting the Archives’ 
department of the Centre de services sociaux de Chicoutimi in order to limit bias results and 
confusion between all the coding. Only  ICD10 coding was used in the final results presented 
here (www.who.org; Table XIV).
Table XIV. ICD 10 codes used (www.who.org).
Diseases ICD10
Circulatory system
Acute rheumatic fever I00-I02
Chronic rheumatic heart diseases I05-I09
Hypertensive diseases I10-I15
Ischemic heart diseases I20-I25
Pulmonary heart disease and diseases of pulmonary circulation I26-I28
Other forms of heart disease I30-I52
Cerebrovascular diseases I60-I69
Diseases of arteries, arterioles and capillaries I70-I79
Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified I80-I89
Other and unspecified disorders of the circulatory system I95-I99
Neoplasms
Malignant neoplasms C00-D48
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Diseases ICD10
Malignant neoplasms, stated or presumed to be primary, of specified sites, except of 
lymphoid, hematopoietic and related tissue C00-C75
Lip, oral cavity and pharynx C00-C14
Digestive organs C15-C26
Respiratory and intrathoracic organs C30-C39
Bone and articular cartilage C40-C41
Skin C43-C44
Mesothelial and soft tissue C45-C49
Breast C50
Female genital organs C51-C58
Male genital organs C60-C63
Urinary tract C64-C68
Eye, brain and other parts of central nervous system C69-C72
Thyroid and other endocrine glands C73-C75
Malignant neoplasms of ill-defined, secondary and unspecified sites C76-C80
Malignant neoplasms, stated or presumed to be primary, of lymphoid, hematopoietic and 
related tissue C81-C96
Endocrine, nutritional and metabolic
Disorders of thyroid gland E00-E07
Insulin-dependent diabetes mellitus E10
Non-insulin-dependent diabetes mellitus E11
Unspecified diabetes mellitus E14
Obesity and other hyperalimentation E65-E68
Of the respiratory system
Acute upper respiratory infections J00-J06
Influenza and pneumonia J09-J18
Other acute lower respiratory infections J20-J22
Other diseases of upper respiratory tract J30-J39
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Diseases ICD10
Chronic lower respiratory diseases J40-J47
Other diseases of the respiratory system
*(Including lung diseases due to external agents, other respiratory diseases principally 
affecting the interstitium, suppurative and necrotic conditions of lower respiratory tract 
and other diseases of pleura)
J60-J99
Of the genitourinary system
Acute renal failure N17
Chronic renal failure N18
Unspecified renal failure N19
3.18. MACCE
A standard definition for MACE (Major Adverse Cardiovascular Events) does not exist, since 
it varies from individual outcomes and studies. In this report, we propose an alternate grading 
system that includes CBVD. To do so, we quantified the diseases from the circulatory system 
with the MACCE score. This helped us distinguish clinically subjects at a higher or a lower 
risk within the FO category. More specifically, it helped stratify more accurately the diseases 
affecting the subjects (Table XV).
Table XV. MACCE grading system.
MACCE Grading System
Score Rank Description
0 Null ○Unspecified risk
1 Low ○Diseases or conditions that result in death on rare or exceptional occasions and 
considered generally to have a benign clinical course
○Low risk of death, heart arrest, CPR, malignant arrhythmia, stroke, RIND, TIA, 
intra-cranial bleeding and major vessel rupture or occlusion
2 Moderate ○Diseases or conditions that do not meet criteria for MACCE 0, 1, 3 or 4.
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MACCE Grading System
Score Rank Description2 Moderate
○Moderate risk of death, heart arrest, CPR, malignant arrhythmia, stroke, RIND, 
TIA, intra-cranial bleeding and major vessel rupture or occlusion
3 High ○Diseases or conditions that result in death or serious morbidity on frequent 
occasions and considered generally to have a malignant clinical course
○High risk of death, heart arrest, CPR, malignant arrhythmia, stroke, RIND, TIA, 
intra-cranial bleeding and major vessel rupture or occlusion
4 Terminal ○No possible chances for improvement with imminent death in the near future. Life 
expectancy measured at the maximum in few months.
CPR= Cardiopulmonary reanimation
3.19. HYPERTENSION
HBP in subjects was determined by the diagnosis found in their medical records. The treating 
physician has previously identified this disorder, and related tests and medical notes were 
found to support this information. In the cases where patients were taking anti-hypertensive 
medication but no HBP diagnosis was mentioned in their file, we referred to their measured 
BP to identify  criteria for HBP (Table XVI) [104]. In addition, HBP of our subjects was also 
related to HBP when initially enrolled in the study.
Table XVI. Hypertension criteria [104, 105].
Target groups Optimal BP values
Hospital/Office BP <140/90
Home BP <135/85
Patients <80 years <140/90
Patients ≥80 years <145/90
DM and/or nephropathy <130/80
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3.20. DIABETES MELLITUS
DM  in subjects was determined by the diagnosis found in the medical records.  Similarly for 
other diagnosis, the treating physician, related tests and medical notes were sought to support 
this information (Table XVII). In the case where patients were taking diabetic medication but 
no DM was mentioned in their chart, we referred to the consulting specialist to ascertain and 
identify which type of DM was affecting the subject.
Table XVII. DM criteria were based on the American Diabetes Association Guidelines 
2010 (www.diabetes.org).
Tests Values
IFG DM
Hemoglobin A1c or glycated hemoglobin (HbA1c; /%) 5.5-6.4 ≥6.5
FPG (/mmol/L) 5.5-6.9 ≥7
Random plasma glucose (/mmol/L) with symptoms of hyperglycaemia (e.g. 
polyuria and polydypsia)
- ≥11.1
Glucose tolerance test (/mmol/L; 75g glucose/2 hours) 7.8-11 ≥11.1
IFG=Impaired fasting glucose
3.21. METABOLIC SYNDROME AND LIPID ABNORMALITIES
The lipid abnormalities and MSY of the subjects were assessed according to the 2004 
International Diabetes Federation Guidelines, Harrison’s Manuel of Medicine (17th Edition) 
and the 2011 American Heart Association guidelines (Tables XVIII and XIX)[106, 107]. It is 
to be noted that if the subject had a MSY when first  seen prior to the enrollment (e.g. in 1995), 
and, by  beginning a healthy  lifestyle, resolved his MSY after enrollment (e.g. in 2008), he was 
still considered as having a MSY by the specialist and the Adjudication Committee. The 
rationale was that the subject was at risk of having sustained a certain degree of “health 
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damage” from that condition. The same applied inversely if the patient developed a MSY 
subsequently  to the start of the study. In addition, lipid disorders were diagnosed following the 
subjects’ lipid status without medication (previously phenotyped by Hamet and his colleagues 
[1]) and complemented with their latest status, if available, in the patient’s hospital record.
Table XVIII. MSY criteria according to the International Diabetes Federation [108].
MSY
Criteria Values
1st 
(obligatory) 
inclusion
Abdominal waist circumference (/cm) 
AND at least two of the following criteria:
♀≥80; ♂≥94
2nd BP (/mmHg) >130/85 (or treated HBP)
3rd FPG (/mmol/L) >5.6 (or diagnosed DM)
4th HDL (/mmol/L) ♀<1.29; ♂<1.03 (or treated for low HDL)
5th TG (/mmol/L) >1.7 (or treated for high TG)
Table XIX. Lipid disorders according to the American Heart Association and Harrison’s 
Manual of Medicine [106, 107].
Criteria for lipid abnormalities
Affection TC
(/mmol/L)
HDL-c
(/mmol/L)
LDL-c
(/mmol/L)
TG
(/mmol/L)
Notes
PH 6.5-8.9 3.36-7.76 Elevated TC or LDL-c; Normal 
value for LDL-c ≤3.34
FCD 6.5-8.9 3.36-7.76 1.7-8.5 Elevated TG + LDL-c and/or TC
DBL 6.5-8.9 ≤3.34 2.8-5.6 Elevated TG and TC
Heterozygous FH 9.0-14.0 Elevated TC
Homozygous FH 14.1-26.0
HTG Normal <1.7 Very high or elevated TG 
without concomitant MSY 
diagnosis
Borderline 
high 
1.7-2.2
High 2.3-5.6
Very high ≥5.7
HALP 0.4-0.9 Decreased HDL-c
Unclassified Requiring more testing to decide the type of abnormality
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3.22. KIDNEY FAILURE
Kidney function was assessed using laboratory results found in subjects’ medical charts. 
Values of eGFR were referenced with the National Kidney Foundation Guidelines to assess 
the renal health status.
Table XX. The five stages of chronic kidney disease of the National Kidney Foundation 
Kidney Disease Outcome Quality Initiative guidelines (www.kidney.org) [109]. Chronic 
kidney disease = kidney damage or eGFR<60 mL/min/1.73 m2 for 3 months. Kidney damage=pathologic 
abnormalities (including blood or urine tests or imaging studies) or markers of damage.
Stage Description eGFR (mL/min/1.73 m2)
1 Kidney damage with normal or ↑ GFR ≥ 90
2 Kidney damage with mild ↓ GFR 60-89
3 Moderate ↓ GFR 30-59
4 Severe ↓ GFR 15-29
5 Kidney failure < 15 (or dialysis)
3.23. OBESITY
Most commonly, the degree of adiposity is evaluated through the body mass index (BMI), 
which correlates with body fat and body fat mass [110-112]. The calculated value for a given 
person is then compared to the predicted age/sex-independent values in order to assess the 
degree of obesity (Table XXI) (WHO; www.who.org). In addition, waist circumference is 
associated with abdominal obesity (♀> 80 cm; ♂> 94) [108] and, as previously mentioned, 
was used to ascertain MSY diagnosis.
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Table XXI. The International Classification of the degree of obesity in adults (both sexes 
together) according to BMI and their relative risk of CV death (www.who.org) [113].
Classification BMI (/kg/m2) CV mortality risk
Underweight <18.50 Low
Normal range [18.50, 25[ None or very little
Overweight (pre-obese) [25.00, 30[ Low
Obese (Classes I to III) ≥30.00 Moderate to very high
3.24. SPECIFIC TESTING: TREADMILL OR STRESS TEST
The degree of CV fitness was considered a complementary  measure, and reflected the physical 
activity. This was best ascertained with the stress test, measured in metabolic equivalents 
(METs), which ascertains the subjects’ fitness on a treadmill. In fact, studies have shown a 
12% survival improvement with every METs increase in exercise capacity and a high 
correlation of increased CV fitness with CHD reduction and overall and CV mortality 
[171-176]. This very important specific test was used to detect or confirm underlying CHD.
3.25. DATA TO BE COLLECTED
The remaining data from 516 subjects will be gathered and analyzed in the future, while the 
data from deceased family members is pending approval from the CAIQ. We will discuss this 
aspect at the end of the Discussion Chapter.
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CHAPTER IV:
Results
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Results
4.
4.1. OVERVIEW
Our study represents an average follow-up  of 11 years of the 343 participants. The Results will 
be presented according to the final data classifications (Figures 9, 13 to 18 and their 
corresponding Tables VII to XII). In other words, each of the six sub-categories will be 
analyzed in detail in the next sections followed by sections summarizing both FO and NFO 
(Table XIII). At any  point, please refer to Chapter III for more details on the explanation, 
organization and presentation of the data. Finally, the relative risk calculations and statistics 
will be presented in the last section of this Chapter.
4.2. CARDIOVASCULAR DISEASES WITH FATAL OUTCOMES
In the following section, we analyze results from 343 subjects with CV affections from FO 
(Table XXII, Figures 13 and 21 A to C). We can see that circulatory  system with FO, which 
include cardiac disease, CBVD, diseases of the pulmonary  circulation, vascular diseases and 
hypertensive diseases, affect 299 out of the 343 participating subjects. In addition, a grand 
total of 1,103 diagnosis have been identified. Furthermore, 555 of those 1,103 are considered 
outcomes, of which 247 are first outcomes for these subjects.
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Table XXII. FO of the circulatory system identified in 343 participating subjects of the 
SLSJ region.
FO of the Circulatory system n Subtype % Total %
Rhythm 
pathologies
CHD
Atrial Bradycardia 97 62.6 8.8
Sinus pathologies 2 1.3 0.2
Non sinus pathologies 21 13.5 1.9
AV AV-Bloc 1’, 2’ and 3’ 28 18.1 2.5
AV dissociation
Accessory pathway
PSVT
Ventricular Left bundle branch block 7 4.5 0.6
Ventricular tachycardia
Ventricular flutter
Ventricular fibrillation 
Cardiac arrest
Other Electromechanical dissociation 0
Diagnosis 155 23.4 14.1
Subjects with outcomes 84 58.7 46.4
Outcomes 103 26.1 18.6
First outcomes 47 27.0 19.0
Angina Unstable angina 24 7.5 2.2
Angina pectoris with documented spasm 1 0.3 0.1
Other forms of angina pectoris 57 17.7 5.2
Angina pectoris, unspecified 15 4.7 1.4
MI Transmur
al
Anterior wall 6 1.9 0.5
Inferior wall 21 6.5 1.9
Other sites 3 0.9 0.3
Unspecified 0
Sub-endocardial 5 1.6 0.5
Unspecified 6 1.9 0.5
Old 3 0.9 0.3
Multiple MI 11 3.4 1.0
Total MI 70 21.7 6.3
Unspecified 
CHD
0
AG Normal 4 1.2 0.4
Mild 
CAD
7 2.2 0.6
Single vessel disease 9 2.8 0.8
Two vessel disease 11 3.4 1.0
Three vessel disease 36 11.2 3.3
Terminal 
CAD
1 0.3 0.1
Grafts (stenosis) 11 3.4 1.0
CABG treatment 2 grafts 9 2.8 0.8
3 grafts 17 5.3 1.5
≥4 grafts 8 2.5 0.7
Unspecified 0
PTCA treatment Low risk 3 0.9 0.3
95
FO of the Circulatory system n Subtype % Total %
HF
(cardiac 
insufficiency)
Valvulopathies 
(non-
rheumatic 
valve 
disorders)
Morphologic 
abnormalities
PTCA treat ent
High risk 28 8.7 2.5
Unspecified 0
Diagnosis 322 48.7 29.2
Subjects with outcomes 86 60.1 47.5
Outcomes 141 35.7 25.4
First outcomes 59 33.9 23.9
LVSD Mild 11 26.8 1.0
Moderate 2 4.9 0.2
Severe 3 7.3 0.3
Unspecified 1 2.4 0.1
RVSD Mild 1 2.4 0.1
Moderate 0
Severe 0
LVDD Mild 19 46.3 1.7
Moderate 3 7.3 0.3
Severe 1 2.4 0.1
Diagnosis 41 6.2 3.7
Subjects with outcomes 29 20.3 16.0
Outcomes 30 7.6 5.4
First outcome 13 7.5 5.3
Ar Mild 11 16.4 1.0
Moderate 4 6.0 0.4
Severe 1 1.5 0.1
As Mild 8 11.9 0.7
Moderate 0
Severe 4 6.0 0.4
Mr Mild 19 28.4 1.7
Moderate 5 7.5 0.5
Severe 1 1.5 0.1
Unclassified 2 3.0 0.2
Ms Mild 2 3.0 0.2
Moderate 0
Severe 0
Unclassified 1 1.5 0.1
Tricuspid 
regurgitation/
stenosis
Mild 7 10.4 0.6
Moderate 1 1.5 0.1
Severe 1 1.5 0.1
Pulmonary 
stenosis, 
regurgitation or 
congenital 
anomaly
Mild 0
Moderate 0
Severe 0
Diagnosis 67 10.1 6.1
Subjects with outcomes 34 23.8 18.8
Outcomes 61 15.4 11.0
First outcomes 25 14.4 10.1
LVH By ECHO 20 29.0 1.8
By ECG 25 36.2 2.3
RVD and LVD 8 11.6 0.7
Other Auricular dilatation, etc. 16 23.2 1.5
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FO of the Circulatory system n Subtype % Total %
Infective and 
inflammatory 
heart disease
Congenital 
defects
Cardiac 
diseases
Ischeamic
Intracranial 
hemorrhage 
CBVD 
diseases
Pulmonary
Diagnosis 69 10.4 6.3
Subjects with outcomes 46 32.2 25.4
Outcomes 56 14.2 10.1
First outcomes 28 16.1 11.3
Endocarditis 0
Myocarditis 0
Pericarditis 1 25.0 0.1
Other Unspecified, Carditis, Rheumatic fever, 
etc.
3 75.0 0.3
Diagnosis 4 0.6 0.4
Subjects with outcomes 2 1.4 1.1
Outcomes 2 0.5 0.4
First outcomes 0
3 100.0 0.3
Diagnosis 3 0.5 0.3
Subjects with outcomes 1 0.7 0.6
Outcomes 2 0.5 0.4
First outcomes 2 0.8 0.8
Subjects affected 173 57.9
Diagnosis 661 59.9
Subjects with outcomes 143 79.0
Outcomes 395 71.2
First outcomes 174 70.4
TIA 17 53.1 1.5
RIND 0
Stroke (Cerebral 
infarction)
Thrombotic infarct 13 40.6 1.2
Embolic infarct 2 6.3 0.2
Diagnosis 32 94.1 2.9
Subjects with outcomes 18 100.0 9.9
Outcomes 23 100.0 4.1
First outcome 12 100.0 4.9
Epidural 0
Subarachnoid 2 100.0 0.2
Intracerebral 0
Diagnosis 2 5.9 0.2
Subjects 0
Outcomes 0
First outcome 0
Subjects affected 27 9.0
Diagnosis 34 3.1
Subjects with outcomes 18 9.9
Outcomes 23 4.1
First outcome 12 4.9
Embolism 9 45.0 0.8
Hypertension Mild 6 30.0 0.5
Moderate 3 15.0 0.3
Severe 2 10.0 0.2
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FO of the Circulatory system n Subtype % Total %
Pulmonary
Diseases of 
pulmonary 
circulation 
Arterial
Venous
Vascular 
diseases
Essential 
(primary) 
Hypertension
Other
Hypertensive 
diseases
Total
Vasculitis Without alveolar hemorrhage 0
With alveolar hemorrhage
Subjects affected 16 5.4
Diagnosis 20 1.8
Subjects with outcomes 14 7.7
Outcomes 17 3.1
First outcome 3 1.2
Cerebrovascular 
disease
Atherosclerosis and unspecified 
hemorrhage
23 21.5 2.1
Thoracic aorta Atherosclerosis (including embolism 
and thrombosis)
16 15.0 1.5
Aneurism 6 5.6 0.5
Dissection 0
Abdominal 
aorta
Atherosclerosis 13 12.1 1.2
Aneurism 2 1.9 0.2
Dissection 0
Renovascular 
disease
Atherosclerosis of renal artery and 
arterioles
7 6.5 0.6
Renal ischemia and infarction 0
Intestinal 
vascular disease
Mesenteric ischemia and/or necrosis 2 1.9 0.0
Atherosclerosis 1 0.9 0.1
Peripheral 
vascular disease
Atherosclerosis and aneurisms of 
arteries of extremities
23 21.5 2.1
Multiple arterial embolisms and 
thrombosis
Other peripheral vascular disease 
(ischemia, etc.)
SVT 6 5.6 0.5
DVT 8 7.5 0.7
Subjects affected 74 24.7
Diagnosis 107 9.7
Subjects with outcomes 65 35.9
Outcomes 89 16.0
First outcome 36 14.6
Controlled 125 44.5 11.3
Uncontrolled 115 40.9 10.4
Unspecified 34 12.1 3.1
Mean BP 
measurements
SBP∆ = 2.00 -
DBP∆ = -6.79 -
Hypertensive Heart disease 1 0.4 0.1
Renal disease 5 1.8 0.5
Heart and renal diseases 1 0.4 0.1
Secondary hypertension 0
Subjects affected 274 91.6
Diagnosis 281 25.5
Subjects with outcomes 31 17.1
Outcomes 31 5.6
First outcome 22 8.9
Participating ♀ subjects 184
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FO of the Circulatory system n Subtype % Total %
Participating ♂ subjects 159
Participating ♀ ♂ together 343
Subjects affected 299
Subjects with outcomes 181
Outcomes 555
First outcome 247
Diagnosis 1103
Figure 21. FO of the circulatory system results for the main sub-types from 299 affected 
subjects of the SLSJ region: A) Diagnosis, B) Outcomes and C) First outcomes.
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4.2.1.CARDIAC DISEASES
A more in depth examination of the Table XXII data indicates that cardiac disease 
(rhythm pathologies, CHD, HF, valvulopathies of non-rheumatic nature, morphologic 
abnormalities, infective and inflammatory  heart disease and congenital defects), affect 
173 of 343 (50.4%) examined subjects or 173 of 299 subjects affected by CV FO 
(57.9%). The diagnosis, outcomes and first outcomes data for cardiac FO are reflected 
below (Figures 22 to 24). This group comprises of 661 out of 1,103 diagnosis (59.9%), 
of which 395 are outcomes (71.2%) and 174 first outcomes (70.4%). It  is to be noted 
that, as previously explained in the Methods Chapter, all percentages (%) are relate to 
their own type.
Figures  22. Diagnosis A) within cardiac disease and B) in comparison to all FO of CV 
origin in 299 affected subjects of the SLSJ region.
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Our results show 155 diagnosed rhythm pathologies (23.4%), comprising 103 outcomes 
(26.1%) and 47 first outcomes (27.0%). Moreover, 322 diagnosis of CHD (48.7%), 
comprising 141 outcomes (35.7%) and 59 first outcomes (33.9%). 
Figure 23.  Outcomes A) within cardiac disease and B) in comparison to all  FO of CV 
origin in 299 affected subjects of the SLSJ region.
Figure 24.  First outcomes A) within cardiac disease and B) in comparison to all FO of 
CV origin in 299 affected subjects of the SLSJ region.
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Following this, 41 diagnosis of HF (6.2%), comprising 30 outcomes (7.6%) and 13 first 
outcomes (7.5%). Next, 67 diagnosis of valvulopathies (10.1%), comprising 61 
outcomes (15.4%) and 25 first outcomes (14.4%). In addition, 69 diagnosis of 
morphologic abnormalities (10.4%), comprising 56 outcomes (14.2%) and 28 first 
outcomes (16.1%). Finally, there were 1 diagnosis of pericarditis of infective and 
inflammatory heart diseases and 3 diagnosis of congenital defects.
4.2.2.CEREBROVASCULAR DISEASES
Looking closely  now at  the data of CBVD, comprised of ischemic diseases and 
intracranial hemorrhage, these affected 27 of 299 affected subjects (9.0%) (Table XXII; 
Figure 25).
Figures  25. Diagnosis A) within CBVD and B) in comparison to all FO of CV origin in 
299 affected subjects of the SLSJ region.
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This group  comprises of 34 out of 1,147 diagnosis (3.1%). More specifically, our results 
show only  2 diagnosis from subarachnoid hemorrhaging (0.2%). Thus, the rest 
originated from ischemic CBVD. In fact, 17 diagnosis originated from TIA (1.5%) and 
15 from stroke (1.2%). Together, they hold 23 outcomes (4.1%), of which 12 were first 
outcomes (4.9%; Figures 21 and 26).
Figure  26.  CBVD A) outcomes and B) first outcomes in comparison to all FO of CV 
origin in 299 affected subjects of the SLSJ region.
4.2.3.PULMONARY CIRCULATION DISEASES
When looking at the data for diseases of the pulmonary  circulation, we see that they 
resulted in 20 of the total diagnosis (1.8%), of which 17 were outcomes (3.1%) and 3 
first outcomes (1.2%; Table XXII; Figures 27). More specifically, 9 diagnosed 
embolisms (0.8%) and 11 pulmonary hypertension (1.0%).
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Figure 27.  Pulmonary circulation A) diagnosis  and B) in comparison to all FO of CV 
origin; C) outcomes and D) first outcomes in comparison to all FO of CV origin in 299 
affected subjects of the SLSJ region.
4.2.4.VASCULAR DISEASES
The data for vascular diseases show that arterial and venous diseases accounted for 107 
diagnosis (9.7%), of which 89 were outcomes (16.0%) and 36 first outcomes (14.6%; 
Table XXII; Figures 28).
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Figure 28.  Vascular A) diagnosis and B) in comparison to all FO of CV origin; C) 
outcomes and D) first outcomes in comparison to all  FO of CV origin in 299 affected 
subjects of the SLSJ region.
More specifically, arterial vascular diseases were responsible for 93 of 107 diagnosis: 
cerebrovascular made up 23 of those diagnosis (2.1%), thoracic aorta 22 (2.0%), 
abdominal aorta 13 (1.4%), renovascular 7 (0.6%), intestinal vascular 3 (0.3%) and 
peripheral vascular diseases 23 (2.1%). On the other hand, venous vascular diseases 
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were mainly due to SVT, responsible for 6 diagnosis (0.5%), and DVT, responsible for 8 
diagnosis (0.7%).
4.2.5.HYPERTENSIVE DISEASES
The last segment that can be observed pertains to hypertensive diseases. Essential HBP 
is a condition found in 274 of 299 affected subjects with CV FO (91.6%). Moreover, it 
encompasses 281 of 1,147 diagnosis (25.5%), 31 outcomes (5.6%) and 22 first outcomes 
(8.9%). In addition, 6 subjects have other connective hypertensive diseases such as 
hypertensive heart, renal or both diseases.
4.3. NON-CARDIOVASCULAR DISEASES WITH FATAL OUTCOMES
In the following section, we analyze results from 343 subjects with affections from non-CV 
FO (Table XXIII, Figures 14 and 29). These include malignant neoplasms, metabolic, lung and 
kidney  diseases and affect 333 out of the 343 participating subjects. A grand total of 1,536 
diagnosis have been identified. Furthermore, 195 of those 1,536 are considered outcomes and 
107 first outcomes for these subjects.
Table XXIII. Non-CV FO results found in 343 participating subjects of the SLSJ region.
Non-CV FO n Subtype % Total %
Malignant 
neoplasms—
Men
Lip, oral cavity and pharynx
Digestive organs
Respiratory and intrathoracic organs
Bone and articular cartilage
Skin
Mesothelial and soft tissue
0
3 12.5 0.2
2 8.3 0.1
0
2 8.3 0.1
2 8.3 0.1
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Non-CV FO n Subtype % Total %
Breast
Male genital organs
Urinary tract
Eye, brain and other parts of CNS
Thyroid and other endocrine glands
Ill-defined, secondary and unspecified sites
Lymphoid, hematopoietic and related tissue
Independent multiple sites
Diagnosis
Subjects affected
Subjects with outcomes
Outcomes
First outcome (/%)
Malignant 
neoplasms—
Women
Lip, oral cavity and pharynx
Digestive organs
Respiratory and intrathoracic organs
Bone and articular cartilage
Skin
Mesothelial and soft tissue
Breast
Female genital organs
Urinary tract
Eye, brain and other parts of CNS
Thyroid and other endocrine glands
Ill-defined, secondary and unspecified sites
Lymphoid, hematopoietic and related tissue
Independent multiple sites
Diagnosis
Subjects affected
Subjects with outcomes
Outcomes
First outcome (/%)
Malignant 
neoplasms
Diagnosis
Subjects affected
Subjects affected also with CVD
Subjects affected by HBP
Subjects with outcomes
Outcomes
First outcome (/%)
Pre-DM AFG and IFT 
Diagnosis
Subjects affected
Subjects affected also with CVD
Subjects with outcomes
0
5 20.8 0.3
3 12.5 0.2
1 4.2 0.1
1 4.2 0.1
3 12.5 0.2
1 4.2 0.1
1 4.2 0.1
24 46.2 1.6
20 44.4 6.0
21 63.6 14.8
18 39.1 9.2
6 30.0 5.6
0
4 14.3 0.3
2 7.1 0.1
0
1 3.6 0.1
0
6 21.4 0.4
3 10.7 0.2
2 7.1 0.1
0
0
1 3.6 0.1
3 10.7 0.2
6 21.4 0.4
28 53.8 1.8
25 55.6 7.5
25 75.8 17.6
21 45.7 10.8
14 70.0 13.1
52 - 3.4
45 - 13.5
40 88.9 12.0
38 84.4 11.4
33 82.5 23.2
46 - 23.6
20 - 18.7
103 100.0 6.7
103 8.0 6.7
103 30.9 30.9
95 92.2 28.5
43 44.8 30.3
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Non-CV FO n Subtype % Total %
Outcomes
First outcome (/%)
DM Type I
Possible Type II
(not confirmed 
by 2nd test)
Diet
Oral Rx
Type II Treated with diet
Oral Rx
Insulin Rx
Unspecified Treated with diet
Oral Rx
Insulin Rx
Diagnosis
Subjects affected
Subjects affected also with CVD
Subjects with outcomes
Outcomes
First outcome (/%)
Metabolic 
syndrome
Previously undiagnosed
Criteria
Diagnosis
Obesity Underweight
Normal
Overweight
Mild
Moderate
High
Diagnosis
Abdominal 
circumference
Men Abnormal >94 cm
Average (/cm)
Women Abnormal >80 cm
Average (/cm)
Diagnosis
Lifestyle Smoking
Alcohol
Drugs
Subjects affected
Diagnosis
Hypoglycemia
Diagnosis
Subjects affected
Subjects with outcomes
Outcomes
First outcome (/%)
43 42.6 22.1
36 54.5 33.6
2 2.1 0.1
1 1.0 0.1
0
33 34.0 2.1
44 45.4 2.9
13 13.4 0.8
3 3.1 0.2
0
1 1.0 0.1
97 7.6 6.3
94 28.2 28.2
90 95.7 27.0
43 44.8 30.3
43 42.6 22.1
26 39.4 24.3
160 100.0 10.4
160 12.5 10.4
5 2.0 0.3
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141 56.2 9.2
66 26.3 4.3
26 10.4 1.7
13 5.2 0.8
251 19.6 16.3
96 47.3 6.3
98.3
107 52.7 7.0
85.4
203 15.9 13.2
101 85.6 6.6
13 11.0 0.8
4 3.4 0.3
109 32.7 32.7
118 9.2 7.7
4 100.0 0.3
4 0.3 0.3
4 1.2 1.2
0
1 1.0 0.5
1 1.5 0.9
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Non-CV FO n Subtype % Total %
Lipid 
abnormalities
PH
FCD
DBL
Heterozygous FH
Homozygous FH
HTG Borderline high
High
Severe
HALP
Unclassified
Diagnosis
Subjects affected
Subjects affected also with CVD
Subjects with outcomes
Outcomes
First outcome (/%)
Metabolic 
causes
Diagnosis
Subjects affected
Subjects with outcomes
Outcomes
First outcome (/%)
COPD
Infection Pneumonia and Influenza
Collagen vascular diseases
Inflammatory
Asthma
Pneumoconiosi
s
Cystic fibrosis
Other ARDS
Lung diseases Diagnosis
Subjects affected
Subjects with outcomes
Outcomes
First outcome (/%)
Renal failure Pre-renal
Renal
Post-renal
Unspecified Ex
Acute
Chronic
Electrolyte 
abnormalities
Sodium (Na+) High
85 24.7 5.5
95 27.6 6.2
3 0.9 0.2
16 4.7 1.0
2 0.6 0.1
9 2.6 0.6
9 2.6 0.6
20 5.8 1.3
85 24.7 5.5
20 5.8 1.3
344 26.9 22.4
273 82.0 82.0
246 90.1 73.9
14 14.6 9.9
14 13.9 7.2
3 4.5 2.8
1280 83.3
333 100.0
96 67.6
101 51.8
66 61.7
32 39.5 2.1
14 17.3 0.9
0
1 1.2 0.1
18 22.2 1.2
0
0
16 19.8 1.0
81 5.3
62 18.6
32 22.5
35 17.9
14 13.1
1 0.8 0.1
8 6.5 0.5
0
25 20.3 1.6
9 7.3 0.6
26 21.1 1.7
9 7.3 0.6
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Non-CV FO n Subtype % Total %Electrolyte 
abnormalities
Sodium (Na+)
Low
Potassium (K+) High
Low
Other
Kidney 
disorders
Diagnosis
Subjects affected
Subjects affected also with CVD
Subjects with outcomes
Outcomes
First outcome (/%)
Total Participating ♀ subjects
Participating ♂ subjects
Participating ♀ ♂ subjects
Subjects affected
Subjects affected also with CVD
Subjects with outcomes
Outcomes
First outcome (/%)
Diagnosis
14 11.4 0.9
8 6.5 0.5
15 12.2 1.0
8 6.5 0.5
123 8.0
68 20.4
28 8.4
17 12.0
20 10.3
7 6.5
184
159
343
333
109
142
195
107
1536
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Figure 29. Non-CV FO results identified in the main sub-types for 333 affected subjects 
of the SLSJ region: A) Diagnosis, B) Outcomes and C) First outcomes.
4.3.1.MALIGNANT NEOPLASMS
Looking closely now at  the data from malignant neoplasms, men have 24 diagnosis 
(1.6%) and women 28 (1.8%), accounting for 52 diagnosis together. Amongst these, 46 
are outcomes (23.6%), of which 20 are first outcomes (18.7%) In total of 45 subjects 
were affected (13.5%), of which 40 were also affected by CV FO (88.9%) and 33 of 
those 45 by HBP (84.4%; Figure 30).
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Figure 30. Neoplasm affected subjects with and without underlying CV FO.
4.3.2.METABOLIC DISORDERS
We found that 103 subjects were at the pre-DM stage with diagnosed IFT and AFG with 
43 outcomes (22.1%) and 36 first outcomes (33.6%; Table XXIII, Figure 31).
Figure 31. Metabolic diagnosis amongst 333 subjects affected by non-CV FO from the 
SLSJ region.
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More than 92% of the diagnosis were for T2D with 90 subjects while only  2 were 
diagnosis with type 1 diabetes (T1D) and 5 with unspecified DM. In addition, none of 
the subjects were previously diagnosed with MSY while, in fact, 50% (160 subjects out 
of 343) were found to meet the criteria for MSY. MSY diagnosis represents 12.5% of 
metabolic disorders and 10.4% of all non-CV FO diagnosis.
Moreover, 251 probands were found to have an unhealthy weight amongst all 
participating subjects (Figure 32). Normal BMI subjects have not been considered in the 
calculations of metabolic disorder in non-CV FO. About 50% of men (96) and women 
(107) were over their normal limit for abdominal circumference of 94 cm and 80 cm, 
respectfully. The average abdominal circumference for men was 98.3 cm and for women 
85.4 cm.
In addition, an unhealthy lifestyle was reported in 109 subjects (31.8%). More 
specifically, there were 101 subjects that  actively smoke or that have smoked, 13 of 
them are alcoholics (0.8%) and 4 taking drugs or narcotics (0.3%). Furthermore, 4 
subjects had hypoglycemia (0.3%) and 1 of those four was a first outcome (0.9%). 
Lastly, lipid abnormalities affect 273 subjects (82.0%), 14 of them are outcomes (13.9%) 
and 3 are first outcomes (2.8%; Figure 33).
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Figure 32. Abnormal weight diagnosis amongst 333 subjects affected by non-CV FO 
from the SLSJ region. Percentages conducted here within the category of obesity and reflect the normal 
weight % in addition to all others. Note that the normal weight calculation is not included in Table XXIV.
Figure 33. Lipid abnormalities within metabolic disorders amongst 333 subjects affected 
by non-CV FO from the SLSJ region.
4.3.3.LUNG DISEASES
The data for lung diseases comprise of 81 diagnosis (5.3%), of which 35 are outcomes 
(17.9%) and 14 first outcomes (13.1%; Table XXIII, Figure 34).
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Figure 34. Lung diseases amongst 333 subjects affected by non-CV FO from the SLSJ 
region.
They affect 62 subjects; COPD represented 40% of all lung diagnosis and infections and 
asthma each 20%.
4.3.4.KIDNER DISORDERS
The last  family  of diseases that can be observed from Table XXIII pertains to kidney 
disorders, which affect 68 subjects (20.4%). Together, they  have 123 diagnosis (8.0%), 
of which 20 are outcomes (10.3%) and 7 first outcomes (6.5%). Renal failure comprises 
of 69 diagnosis (4.5%), while electrolyte abnormalities form 46 diagnosis (3.0%). 
Finally, there are 8 diagnosis (1.5%) from other kidney disorders.
4.4. ALL OTHER FATAL OUTCOMES
In the following section, we analyze results from 343 subjects with affections from all other 
FO (Table XXIV, Figure 15 and 35). These include disorders of mental and behavioral, 
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nervous, digestive, accidental, other and unknown origins, and affect 62 out of the 343 
participating subjects. In addition, a grand total of 81 diagnosis have been identified. 
Furthermore, 30 of those 81 are considered outcomes and, 11 are first  outcomes. There were 6 
mental and behavioral disorders (7.4%), 18 of the nervous system (22.2%), 17 of the digestive 
system (21.0%), 9 accidents (11.1%) and 31 of other known causes (38.3%).
Table XXIV. All other FO results from 343 participating subjects of the SLSJ region.
All other FO n %
Mental and behavioral
Nervous system Alzheimer’s disease, etc.
Digestive system Other (e.g. sub-occlusion/ileum)
Accidents
Other Bleeding, Enterocolitis due to Clostridium difficile, etc.
Unknown
Total Participating ♀ subjects
Participating ♂ subjects
Participating ♀ ♂ subjects
Subjects affected
Subjects with outcomes
Outcomes
First outcome (/%)
Diagnosis
6 7.4
18 22.2
17 21.0
9 11.1
31 38.3
0
184
159
343
62
27
30
11
81
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Figure 35. All other FO in 62 affected subjects from the SLSJ region.
4.5. SUMMARY OF FATAL OUTCOMES
The following table and figures depict the summary of FO in participating subjects (Table 
XXV, Figures 36 and 37). In summary, a grand total of 337 subjects (98.3%) were affected by 
all three causes, 236 of them had 780 outcomes, of which 365 were first outcomes. Lastly, a 
grand total of 2,720 diagnosis were identified in the participating subjects. As such, there were 
299 subjects affected by CVD, 333 from non-CVD and 62 by all other diseases. In addition, 
109 of those affected by  non-CVD (32.3%) and 58 by all other diseases (17.2%) have 
concomitant CV FO. Lastly, there were 181 subjects with CV outcomes (76.7%), 142 from 
non-CV (60.2%) origin and 27 all other causes (11.4%; Figure 37 B). 
Diagnosis from CV FO totalized 1,103 (55.9%), from non-CV 1,536 (41.8%) and from all 
other causes 81 (3.0%; Figure 37 A). Furthermore, outcomes from CVD totalized 555 
(71.2%), from non-CVD 195 (25.0%) and from all other causes 30 (3.8%) (Figure 37 C). 
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Finally, first outcomes from CVD totalized 247 (67.7%), from non-CVD 107 (29.3%) and 
from all other causes 11 (3.0%; Figure 37 D).
Table XXV. FO summary for 343 participating subjects of the SLSJ region (total n = 343; 
184 ♀and 159 ♂).
DWM CV Non-CV Other
n % n % n %
Subjects •Affected
•+ CVD
•Outcomes
Outcomes
First outcomes
Diagnosis
Total
299 88.7 333.0 98.8 62.0 18.4
109.0 32.3 58.0 17.2
181 76.7 142.0 60.2 27.0 11.4
555 71.2 195.0 25.0 30.0 3.8
247 67.7 107.0 29.3 11.0 3.0
1103 40.6 1536.0 56.5 81.0 3.0
Subjects affected 337 98.4
Subjects with outcomes 236
Outcomes 780
First outcome % 365
Diagnosis 2720
Figure 36. Subjects affected by all FO, focussing on their concomitance with CV FO.
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In summary, non-CV FO had the most diagnosis. Nevertheless, CV FO had the most impact 
when it came to the most subjects with outcomes, outcomes themselves and first outcomes 
(Figure 37).
Figure 37. Summary of A) diagnosis, B) subjects with outcomes, C) outcomes and D) first 
outcomes for FO in 337 affected subjects of the SLSJ region.
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4.6. CARDIOVASCULAR DISEASES WITHOUT FATAL OUTCOMES
In the following section, we analyze results from 343 subjects with affections from CV NFO 
(Table XXVI, Figure 16). There are three main diseases in the sub-category: cardiac diseases, 
vascular diseases and hypotension. Cardiac diseases, which included rhythm pathologies and 
non-rheumatic valve disorders affected 98 of 105 affected subjects (93.3%), venous vascular 
diseases 10 (6.4%) and hypotension 7 (6.7%). Moreover, cardiac diagnosis represented 14.9%, 
venous vascular diseases 1.1% and hypotension 0.7% of the 934 total diagnosis from NFO. In 
summary, a total of 156 diagnosis have been identified affecting 105 subjects.
Table XXVI. NFO of the circulatory system identified in 343 participating subjects of the 
SLSJ region.
NFO of the circulatory system n Subtype % Total %
Cardiac 
diseases
Rhythm pathologies
Non-rheumatic valve disorders
Subjects affected
Diagnosis
Vascular 
diseases
Venous
Subjects affected
Diagnosis
Hypotension
Subjects affected
Diagnosis
Total Participating ♀ subjects
Participating ♂ subjects
Participating ♀ ♂ subjects
Subjects affected
Diagnosis
Atrial 59 42.4 37.8
AV 2 1.4 1.3
Ventricular 56 40.3 35.9
Aortic 17 12.2 10.9
Mitral 5 3.6 3.2
Tricuspid 0
Pulmonary 0
98 62.8
139 89.1
10 6.4
10 9.5
10 6.4
Low risk 2 28.6 1.3
High risk 1 14.3 0.6
Unclassified 4 57.1 2.6
7 6.7
7 4.5
284
159
343
105
156
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4.7. NON-CARDIOVASCULAR DISEASES WITHOUT FATAL OUTCOMES
343 subjects were affected with non-CV NFO (Table XXVII, Figure 17). There are three main 
diseases in the sub-category: benign neoplasms, lung and kidney diseases. We can see that 
benign neoplasms, for both, men and women, totalized 44 (73.3%), lung diseases 7 (11.7%) 
and kidney  disorders 5 (8.3%). In summary, a total of 60 diagnosis have been identified 
affecting 53 subjects.
Table XXVII. Non-CV NFO found in 343 participating subjects of the SLSJ region.
Non-CV NFO n Subtype % Total %
Benign 
neoplasms
Men Lip, oral cavity and pharynx
Digestive organs
Respiratory and intrathoracic organs
Bone and articular cartilage
Skin
Mesothelial and soft tissue
Breast
Male genital organs
Urinary tract
Eye, brain and other parts of CNS
Thyroid and other endocrine glands
Lymphoid, hematopoietic and related 
tissue
Other
Independent multiple sites
Women Lip, oral cavity and pharynx
Digestive organs
Respiratory and intrathoracic organs
Bone and articular cartilage
Skin
Mesothelial and soft tissue
Breast
Female genital organs
Urinary tract
Eye, brain and other parts of CNS
Thyroid and other endocrine glands
0
4 9.1 6.7
1 2.3 1.7
0
6 13.6 10.0
1 2.3 1.7
0
0
1 2.3 1.7
0
0
0
0
0
0
5 11.4 8.3
0
0
5 11.4 8.3
1 2.3 1.7
5 11.4 8.3
6 13.6 10.0
1 2.3 1.7
0
2 4.5 3.3
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Non-CV NFO n Subtype % Total %
Lymphoid, hematopoietic and related 
tissue
Other
Independent multiple sites
Subtotal Diagnosis
Lung diseases
Kidney 
disorders
Total Participating ♀ subjects
Participating ♂ subjects
Participating ♀ ♂ subjects
Subjects affected
Diagnosis
0
3 6.8 5.0
3 6.8 5.0
44 100.0
7 15.9
5 11.4
184
159
343
53
60
4.8. ALL OTHER DISEASES WITHOUT FATAL OUTCOMES
In the following section, we analyze results from 343 subjects with affections from all other 
NFO (Table XXVIII, Figure 18). In summary, a total of 718 diagnosis have been identified 
affecting 252 subjects. Details of each disease are found below.
Table XXVIII. All other NFO identified in 343 participating subjects of the SLSJ region.
All other NFO n %
Mental and behavioral Anxiety
Other
Nervous system
Eye and adnexa Cataracts, etc.
Ear and mastoid process
Digestive system
Genitourinary system
Endocrine, nutritional and metabolic Hypothyroidism
Hyperthyroidism
Blood and blood-forming organs and certain 
disorders involving the immune mechanism
Anemia, etc.
Other
Musculoskeletal system and connective tissue
Accidents
Other
Unknown
15 2.1
6 0.8
8 1.1
75 10.4
8 1.1
141 19.6
96 13.4
51 7.1
2 0.3
93 13.0
9 1.3
144 20.1
14 1.9
55 7.7
1 0.1
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All other NFO n %
Total Participating ♀ subjects
Participating ♂ subjects
Participating ♀ ♂ subjects
Subjects affected
Diagnosis
184
159
343
252
718
4.9. SUMMARY OF DISEASES WITHOUT FATAL OUTCOMES
The following table and figures depict the summary  of NFO in participating subjects (Table 
XXIX, Figures 38). A grand total of 273 subjects (79.6%) were affected, totalizing 934 
diagnosis. As such, 92.3% of subjects (718) were affected by all other diseases, while only 
38.5% (105) by CVD and 19.4% (53) by non-CVD. Similarly, 76.9% of diagnosis (718) 
originated from all other diseases, but only from 16.7% (156) from CVD and 6.4% (60) from 
non-CVD.
Table XXIX. Summary for NFO in 343 participating subjects of the SLSJ region (total n 
= 343; 184 ♀and 159 ♂).
NFO CVD Non-CVD Other diseases
n % n % n %
Subjects affected
Diagnosis
Total
105 38.5 53 19.4 252 92.3
156 16.7 60 6.4 718 76.9
Subjects affected 273 79.6%
Diagnosis 934
123
Figure 38.  Summary of A) diagnosis and B) subjects affected for NFO in 273 affected 
subjects of the SLSJ region.
4.10. RELATIVE RISK
In this section, we evaluate the RR for diseases in our ‘exposed’ subjects versus the ‘control’ 
population of SLSJ region (Table XXX). If necessary, please refer to Chapter III for more 
detailed specifications on the calculations involved. Interestingly, we observe that there is a 
threefold risk increase in our subjects to develop disease from the circulatory  system 
compared to the general population of SLSJ, and this is statistically  significant. Furthermore, 
the risk of developing isolated malignancies significantly  decreased by half in our sample 
while it almost doubled when taken into account with CVD. In addition, the risk for HBP was 
one and a half higher.
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Table XXX. RR calculated for various diseases in our study. Note that the reference values 
for ‘c’ and ‘d’ come from Lapierre et al. [19].
Disease a∮ b∮ c∮ d∮ RR Z∮ P-value
Circulatory system** 1,103 1,617 3,878 22,994 2.810 23.545 <0.0001
Hypertension** 281 822 44,874 221,054 1.510 7.971 <0.0001
HBP with CVD** 274 69 88 255 3.114 11.853 <0.0001
DM 97 1,439 15,313 239,266 1.050 0.494 0.62
Malignant neoplasms** 52 1,484 2,019 24,853 0.451 5.778 <0.0001
Malignant neoplasms + 
HBP**
38 52 7,474 19,398 1.518 3.375 0.0007
Malignant neoplasms + 
circulatory system**
1,155 1,565 5,897 20,975 1.935 26.289 <0.0001
Obesity with CVD** 246 97 172 171 1.430 5.624 <0.0001
Non-CV** 1,536 1,184 5,374 8,998 1.510 20.616 <0.0001
All other** 81 2,639 5,120 9,252 0.084 22.558 <0.0001
All non-CV and other** 1,617 1,103 10,494 14,372 1.409 19.592 <0.0001
Legend∮:
** = highly significant
a = affected individuals in our study
b = unaffected individuals in our study
c = affected individuals in SLSJ region 2006-2007
d = unaffected individuals in SLSJ region 2006-2007
Z = Z test (Z statistics) performed
4.11. CHI SQUARE TEST
We used the Chi square ( χ2 ) test if the large differences in observed between exposed 
outcomes are probable in our sample (see Chapter III). As such, our results show a high degree 
of significance for all data tested (Table XXXI). In fact, we obtained a χ2 value of 1,575.348 
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for data of diseases of the circulatory system (p<0.0001), while this value decreased a 100 
times for Non-CV diseases (p<0.0006). As for malignant neoplasm, when considered with 
malignant neoplasm the χ2 value increases tenfold.
Table XXXI. Chi square ( χ2 ) test results with their degrees of freedom (ν) and a two-
tailed P-value for various diseases in our study. Note that  the expected values were 
calculated from Lapierre et al. [19].
Disease w∮ x∮ y∮ z∮ χ2 ν P-value
Circulatory system** 1,103 383 1,617 2,337 1,575.348 1 <0.0001
Hypertension** 281 69 62 274 815.392 1 <0.0001
HBP with CVD** 274 88 69 255 528.807 1 0.0001
Malignant neoplasms** 52 125 1484 1411 46.409 1 <0.0001
Malignant neoplasms + 
HBP**
38 15 15 38 49.188 1 <0.0001
Malignant neoplasms + 
circulatory system**
1155 597 1565 2123 668.210 1 <0.0001
Obesity with CVD** 246 172 97 171 63.861 1 0.0001
Non-CV** 1,536 1,624 1,184 1,096 11.834 1 0.0006
All other** 81 1,505 2,639 1,215 3,016.311 1 0.0001
All non-CV and other** 1,617 1,986 1,103 734 254.066 1 0.0001
Smokers with CVD** 70 50 30 50 16.000 1 0.0001
Legend∮:
** = highly significant
w = observed affected individuals in our study
x = expected affected individuals in our study
y = observed unaffected individuals in our study
z = expected unaffected individuals in our study
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CHAPTER V:
Discussion
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Discussion
5.
5.1. OVERVIEW
Our study represents an average follow-up of 11 years of the 343 participants. In this Chapter, 
we will discuss the relevance and importance of the reported results. In doing so, we hope to 
paint a CV portrait in order to eventually identify the risk factors for patients with similar 
familial and phenotypic characteristics (dyslipidemia +/- obesity). A descriptive overview of 
the population sample can give an idea of the group morbidities and possible mortality  causes. 
We will see what affections are found in our segment of population. As previously mentioned, 
it is hard to isolate the different components of CVD. They  are multifactorial traits with 
complex interactions from both genetic and environmental factors. Previous findings showed 
that the degree of genetic homogeneity increased by selecting families with a high prevalence 
of HBP and even more in a subset with high and low risks of early mortality [13].
In summary, we will start by discussing the overall data for FO, NFO and RR, following result 
organization. Finally, we will address the limitations of the present study and its techniques.
5.2. DISEASES WITH FATAL OUTCOMES
5.2.1.CARDIOVASCULAR VS. NON-CARDIOVASCULAR DISEASES
The mortality  rates from CVD in Canada and Quebec are 32.1% and 25.2%, 
respectively, which ranks them first and second of mortality causes [8, 11]. Interestingly, 
we notice that 59.9% of the diagnosis in our subjects (661 of 1,103 CV FO diagnosis) 
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come from cardiac diseases, the most frequent cardiac disease being CHD representing 
48.7% (322 of 661 cardiac FO diagnosis). High elevation of this type of diseases in our 
cohort seems to explain the high elevation of mortality events from CVD. This also can 
suggest that our FO classification was valid, but this will be discussed later on.
The depth of CV FO affection is vast. In fact, CV FO affect purely 43% of subjects, 
while 109 of 333 affected subjects with non-CVD FO have also a concomitant CV FO 
(Figure 36). Furthermore, 58 out of the 62 subjects from other FO also suffer from a CV 
FO. Thus, 67.1% of all subjects from this category have a CV FO. This highlights the 
importance of CVD in this sample of 343 subjects from SLSJ. While no statistical 
testing has been done, the real number of affected participants gives an idea of the 
importance of CVD. It would be interesting to compare the number of participants 
affected with only CVD to those with concomitant CVD to those without CVD.
In fact, our sample showed a threefold risk increase in developing CVD (p<0.0001; 
χ2=1,575.348), while it diminished by half when compared to non-CVD (p=0.0006; 
χ2=11.834) in the population of SLSJ. This is very interesting since it supports our 
finding that CVD predominated in the number of outcomes and first outcome over all 
other causes (discussed in the following section).
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5.2.2.DIAGNOSIS VS. OUTCOMES VS. FIRST OUTCOMES
As previously  stated, CV and non-CV FO are the leading causes of morbidity  and 
mortality in North America [3, 5, 8]. Our classification into three subcategories of FO 
showed that CVD accounted for 40.6% of all diagnosis, non-CVD for 56.4% and all 
other diseases 3.0% (Figure 38). This seems to suggest  that our sample is mainly 
affected by non-CV FO. However, as mentioned in the previous section, CV FO seemed 
to affect more subjects when looking at combinations of CV and other diseases. As such, 
our outcomes and first outcomes reflect this tendency and highlight the difference 
between our category of diagnosis vs. outcomes and first outcomes. In fact, there is a 
complete reversal in importance: (1) 71.2% of all outcomes are from CVD (elevation of 
almost 30% from CVD diagnosis; drop of almost 31% for non-CVD) and (2) 67.7% of 
all first  outcomes from CVD (elevation of almost 27% from CVD diagnosis; drop of 
almost 27% for non-CVD).
The reason why the importance of CVD rises might come from our definitions of 
diagnosis, outcomes and first outcomes. The fact that outcomes and first outcomes only 
appear at the entry  of the study gives us the opportunity to see what diseases developed 
during the last 11 years of this follow-up. At the same time, it distinctly focuses on these 
diseases without having middle ground for affection with both CV and non-CV/other 
FO. In other words, this pre-selecting criterion also seems to elevate the degree of 
homogeneity  for CVD and may be considered as a possible guideline when analyzing 
with proper statistical testing, this population in future studies.
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Finally, the average age for outcomes occurrence in men was 55, while for women was 
61. Following the criteria for early onset of CVD and risk of early mortality, men from 
this sample are at the borderline for early onset or early  mortality since the age interval 
of early  risk is between 25 to 55 years of age [48, 105]. On the other hand, women fall 
directly  into their respective interval for early  onset or early  mortality (from 25 to 65 
years of age). These results support literature findings that post-menopausal women are 
more at risk towards CVD and that men are more at risk towards CVD than pre-
menopausal women [87]. These preliminary data also raise the question of the 
stringency and validity of the age criteria for early onset of CVD and risk for early 
mortality.
5.2.3.CARDIOVASCULAR RISK FACTORS
Historically, it is only during the last half century, with the beginning of the Framingham 
Heart Study, that the scientific community and general population have started to be 
aware of the importance of prevention and treatment of CV risk factors before the 
disease onset [114]. These have been discussed in length in the Chapter II. Unless 
otherwise specified, the results discussed in this section relate to Table XXIII (non-CV 
FO).
5.2.3.1.HYPERTENSION AND OBESITY
The dangers and deleterious effects of HBP are well known as well as the reason 
why it is one of the main risk factors for CVD morbidity and mortality [50, 105]. 
In our sample, 274 out of 343 subjects were affected by hypertensive diseases 
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(79.9%; Table XXII). Moreover, 6 of them had HBP in conjunction with heart, 
renal or both diseases. As simple compilation of the affected subject showed how 
important this disease is in our population, and was previously  reported [1]. 
Obesity is another crucial risk factor for CVD. Statistic Canada reports that 68% of 
men and 53% of women are overweight or obese [115]. In fact, we report  that only 
92 of 343 participating subjects had a normal BMI (27.5%), indicating that  71.5% 
were at least overweight (only 1.4% are underweight; Figure 32).
Furthermore, previous research on the French-Canadian families SLSJ region of 
Quebec showed that the genetic entities for HBP and obesity were distinct [2, 17]. 
Together, we identified 210 subject both with both HBP and obesity yet they only 
had 59 CV FO (28.1%). However, our results showed that, separately, 60.6% of 
affected subjects with HBP (χ2=528.807, p=0.0001) and 59.8% with obesity had 
an also an underlying CV FO. In addition, the RR was high in both cases in 
combination with CVD in our sample compared to the rest of SLSJ region: 
threefold for HBP (p<0.0001) and one and a half for obesity (p<0.0001).
Abdominal obesity is the first obligatory criteria for MSY and an additional risk 
for CVD by itself [112, 116] and also contributed to the risk factors for CV FO. 
Our subjects had abnormal or elevated average abdominal circumferences for 96 
out 159 men, and 107 out of 184 women (98.3 cm and 85.4 cm, respectively). To 
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conclude, our study sample had already risk factors for CVD that might explain 
previous results for diagnosis, outcomes and first outcomes for CV FO.
5.2.3.2.PRE-DIABETES AND DIABETES MELLITUS
Until the 1800s, DM was to be treated by  the Rollo diet, consisting mainly  of meat 
[117]. Subjects at the stage of pre-diabetes, e.g. IFG or AFG, are at high risk to 
develop DM and even CVD [118]. After consulting with a specialist, we identified 
between 50 to 60% of the subjects previously undiagnosed with DM with 
laboratory results confirming the pre-DM stage, or T2D (not mentioned in the 
hospital charts or untreated). Nevertheless, it is quite possible that the subject(s) 
was/were made aware of their medical situation but the diagnosis was not recorded 
properly  in their hospital chart. Notwithstanding this information, we have found 
that 103 of 343 participating subjects (30.0%) were classified as pre-DM  affected, 
and 43 of these (42.6%) were outcomes. More specifically, 95 out of the 103 
subjects (91.3%) had concomitant CV FO, which contributed to the CV impact 
mentioned above.
Furthermore, we identified 2 T1D subjects, 93 T2D and 4 with unspecified DM 
(could not be confirmed by hospital notes). DM had also 43 outcomes (22.1% of 
all non-CV outcomes), of which 26 were first outcomes (24.3% of all non-CV first 
outcomes). In addition, 7 of the 93 subjects with T2D were previously 
undiagnosed for DM in their hospital charts but were classified as diabetics 
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according to their laboratory  results and medication. Similarly to the pre-diabetes 
subjects, 94.7% with DM  were affected also by  CV FO. In comparison, in the 
subjects without diabetes, the percentage of affected subjects by  also CV FO 
dropped to 60.9%, supporting the literature indicating that people with DM have a 
higher prevalence of CVD [119]. However, this will be done in the future study 
and will have to be supported by appropriate statistical testing.
5.2.3.3.CHOLESTEROL
Cholesterol is another risk factor for CV FO that may contribute to the high 
number of outcomes and first outcomes. In fact, DLP is a major risk factor for 
CVD [71, 72]. It is important in CV prevention to detect early cholesterol-related 
health problems, since they can be treated quite efficiently with medication and the 
counter gain is significant in avoiding or slowing down the onset of CVD. This is 
especially important in rarer cases of heterozygous or homozygous FH where 
subjects might be at risk of dying even before the age of 25 years from CVD. In 
addition to very  high CHOL in both FH forms, there can be concomitant severe 
HTG, which aggravates a subject’s health situation and requires fast treatment.
We noted 344 diagnosis of lipid abnormalities out of 1,536 total diagnosis for non-
CV FO (22.4%). These were affecting 273 out of 343 subjects (79.6%). When 
cross-referencing those subjects to the ones with CV FO, we obtain a total of 246 
subjects (71.7% of participating subjects) with both CV and non-CV FO. This 
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again may contribute to the CV importance mentioned above. Moreover, we found 
16 cases of heterozygous FH and 2 cases homozygous FH, which are rarer but 
potentially deadly as previously mentioned.
5.2.3.4.KIDNEY DISORDERS
Renal disorders, e.g. diminished GFR, have been known to be associated to an 
increased prevalence of prior CVD, CV risk factors and overall death [109, 120, 
121]. Within our study, we found 35 diagnosis of chronic and acute renal failure 
for 29 subjects. Amongst those diagnosis, we also found 20 outcomes and 7 first 
outcomes for 17 subjects. In addition, we have 13 subjects with renal 
atherosclerosis, 5 subjects with renal hypertensive diseases and 1 with both heart 
and renal hypertensive diseases. Lastly, 28 out of the 68 subjects also have 
concomitant DWM from CVD within the segment of kidney failure.
5.2.3.5.LIFESTYLE AND CARDIOVASCULAR DISEASES
An unhealthy lifestyle has been known to increase the risk of CV FO [116, 119, 
122, 123]. In addition, tobacco use is imbedded in the global socio-cultural and 
economic dimensions and Tobacco Industry lobbying targets ideologies and way 
of thinking of young adults and/or adolescence [90, 124, 125]. This reflects the 
importance of prevention and roles of physicians in our society  to make their 
patients aware of the risks. However, the problem lies in the patient’s will to 
change. Another issue is the popular urban myths of people who led very 
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unhealthy lifestyle, excessive smoking, eating and alcoholism, and lived a long 
‘healthy’ life. Nevertheless, it is important to look at this with objective and critical 
thinking. In all statistics, there are exceptions, but this might apply  only to a small 
segment of the population possibly due to a strong ‘defensive’ genetic background 
protecting against FO, such as CVD.
In fact, our sample showed that 101 of 343 participating subjects smoked (29.4%), 
and 109 (31.8%) had an unhealthy  lifestyle, such as smoking, alcoholism and drug 
abuse. Interestingly, about half of the non-smokers were affected by FO CV, while 
this rose to 70% in smokers (χ2=16.000, p<0.0001). This supports the previously 
mentioned literature that smoking puts subjects at risk for CVD.
5.2.4.CANCER AND CARDIOVASCULAR DISEASES
CVD may be linked to malignancies [46, 47, 126]. The rationale for coexistence of CVD 
and cancer risk is not yet  fully  understood. Nonetheless, overstimulation and even higher 
proliferation of smooth muscle cells in HBP creates a bigger cell turnover [25, 127-129]. 
In doing so, mutations occur more frequently, which in itself is a risk for cancer.
In the case of non-CV FO, malignant  neoplasms account for 52 diagnosis  affecting 45 
of 333 affected subjects. At first  look, it may be argued that this ratio of subjects 
compared to other diseases of the same group is not that high. Nevertheless, our results 
show that 88.9% of these subjects are also affected by CVD. More interestingly, 84,4% 
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of cancer subjects suffer from also from HBP. In fact, our results show a 1.5 increased 
risk (p=0.0007) in our sample to suffer both from HBP and cancer (p<0.0001, 
χ2=49.188) than from cancer alone, which was actually  diminish by half (p<0.0001). 
Thus, this might hold a partial explanation to the higher outcomes and first outcomes 
that might be linked to overall death from cancer and/or developing it, but further data 
collection and statistical testing will be required.
Lastly, the RR for developing malignancies yielded a twofold decrease in occurrence in 
our sample in contrast in to the general population of SLSJ (p<0.0001, χ2=46.409). 
Interestingly, this result changed when we examined the combination of malignant 
neoplasms with CVD. In fact, it  grew twice as much in our sample (p<0.0001, 
χ2=668.210). As such, this would support the literature that there exist a link between 
CVD and cancers.
5.3. DISEASES WITHOUT FATAL OUTCOMES
We also analyzed NFO in comparison to FO. Among these, we note a complete reversal of 
importance which was to be expected (Table XXIX; Figure 38). The results showed that the 
importance of CVD fell to 16.7% and non-CV to 6.4%  while all others rose to 77%. This may 
suggest that CVD (and non-CVD) are more often FO than NFO and when they occur, they  put 
the subject at a rising risk over time. While there are many NFO, the patient can be treated and 
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managed more efficiently, which diminishes the overall risk on the subject’s morbidity and 
mortality.
5.4. LIMITATIONS OF THE CURRENT STUDY
In this last section, we will discuss some variables that influenced the development of this 
study.
5.4.1.DATA COLLECTION
5.4.1.1.COMMITTEE APPROVALS
Approval from the CAIQ has been previously  been obtained but  had expired in 
2006. A new submission has been sent in July 2011 after contacting the CAIQ on 
numerous occasions because we were assured that this would be the most efficient 
way to proceed. At the moment of the writing of this thesis, we are still awaiting 
the approval to contact the ISQ and pursue the study  of mortality events to 
determine early mortality within each family of the participating subjects.
The fatal outcomes deserve further analysis, pending the permission from the 
CAIQ. It is to be noted that the data from deceased subjects that were enrolled 
directly  in the study have not been showed in this thesis. It  will be relevant to 
analyze the nature of these lethal outcomes in relation to early  mortality. In fact, 
this initial exploration of the data may  result in re-examining the age criteria for 
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early mortality (25 to 55 years of age for men and 25 to 65 for women). The 
presented data will assist us at determining more objectively those criteria.
5.4.1.2.GATHERING PROCESS
When examining the subject at the Centre de santé et des services sociaux of the 
Chicoutimi Hospital in the SLSJ region, not all the hospital charts contained a 
systematic coding of ICD. Many  of them were not yet coded following this system 
during the data gathering of July 2010. For those that were, some were coded by 
ICD9 and converted to ICD10 while others directly by ICD10 (as explained in 
Chapter III: Methods).
In addition, many subjects had their records destroyed by the archives, limiting the 
availability of laboratory  results and specific tests for several cases. This was 
unfortunate since much information could have been gathered from those data. On 
a more positive note, after consulting and explaining this problem in length to the 
Chicoutimi Research Center’ law representative, a request was sent the Hospital’s 
Archives to stop  the chart destruction process for the participating subjects for the 
next 25 years. The request was approved by the competent authorities. 
During the data gathering, we noted that 37 patients did not consent to continue 
this study and 65 had missing consent. Those consents were kept at the Chicoutimi 
Research Center and were, unfortunately, not all found. Further clarification and 
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investigation is required for these. When leaving the collection site in July 2010, 
an order was issued to find these consents and clarify the status of the subjects’ 
who did not consent with the Chicoutimi Ethics Committee. In fact, it was unclear 
if they actually refused their data to be used in further studies or just to be 
contacted for new procedures in the future. However, the Center’s Administrative 
Coordinator decided they were not to be included until further clarification.
In addition, there were 4 out of 380 analyzed subjects that were not associated to 
any families in our database but were participating in the study. It  will be 
important to find out where these 4 subjects fall in the families in order to elevate 
the statistical value of the present and future studies on the data gathered. This also 
might have been a clerical error on the subjects’ ID. 
Finally, the geographical location of the Chicoutimi site limited the time for data 
collections and will have to be completed in the future. On the other hand, the data 
from the subjects that  have moved to Montreal (second collection site) have not 
been gathered yet. It was planned to first finish with the Chicoutimi subjects 
before starting the second group. Also, these two groups have not received care at 
the same Hospital sites, which may lead to selection and information bias. 
Montreal subjects are not presented in the current  study. Furthermore, if the 
subjects from Chicoutimi had received care elsewhere, hospital charts can be 
transferred for review, which limits the information bias. Moreover, the Centre de 
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santé et de services sociaux de Chicoutimi is the largest hospital system in the 
SLSJ region and offers the possibility  for advance testing (both clinical and 
laboratory), which is not available in smaller cities of the region. This is another 
aspect to be worry about for future data collection(s).
5.4.2.DATA CLASSIFICATIONS AND DIAGNOSIS
As previously mentioned in Chapter III: Methods, our dichotomous data classifications 
have been decided with the help  of an Adjudication Committee and the recommendation 
of a specialist. Each diagnosis, has been examined in depth by the consulting specialist 
in order to verify the data and check for false positive or negative results for the purpose 
of this study. In conjunction, the diagnosis were validated by the Adjudication 
Committee. However, a potential misclassification of the diseases cannot be excluded. 
Fortunately, the impact would not be as important as it could be because the data were 
not separated randomly into FO and NFO categories. It  followed experienced 
advisement and was done according to the potential severity of diseases. In the end, 
some disease are life threatening (e.g. malignant  neoplasm, etc.) while others are not 
(e.g. benign neoplasm, etc.).
Furthermore, a second degree of classification for CV FO, i.e. MACCE score, has been 
added to help quantify if the diagnosis was at  high or lower risk within the category of 
FO. The data may also suggest that CVD are more often FO than NFO. When this 
occurs, it would put the subject more at risk over time, which would yield false positive 
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results. In other words, this additional measure helped differentiate between patients 
with severe CV (e.g. CHD, HF, etc., with MACCE≥3/4) and non-CV FO (e.g. malignant 
neoplasms, DM, etc.), from patients with ‘milder’ CV (e.g. bradycardia, etc., 
MACCE≤1) and non-CV FO. In summary, we tried to objectively separate and 
distinguish diseases into qualifying categories in order to better understand and describe 
this sample population.
5.4.3.MACCE SCORING SYSTEM
The MACCE score system has been adapted for the present study from the MACE 
grading system. In addition to the CVD, we combined them to CBVD to obtain the 
MACCE scoring system. In fact, this is why we computed a total MACCE score and an 
individual MACCE score for each disease. These assisted us in stratifying individuals 
with multiple CV FO for further analyses 
The cumulative MACCE score was used to give an idea of the relative importance of 
CV FO in each subject. In fact, this may also show that some individuals with an 
elevated cumulative risk for CVD are at higher risk of outcomes. This may be illustrated 
by two individual examples:
Subject A is a 69-year-old woman with a total MACCE score of 3. She has HBP with 
MACCE=3/4. As HBP is a CV FO, we classify this subject in CV FO, because HBP can 
have many deleterious effects on several organs, e.g. heart, brain, kidney and lung;
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Subject B is an 80-year-old woman with a total MACCE score of 11. If we examine only 
her CV status, she has bradycardia with MACCE=1/4, ischemic heart  disease with 
MACCE=3/4 (multiple MI, PTCA with multiple stents and three vessel disease), mild 
HF with MACCE=1, mitral valve regurgitation with MACCE=1, LVH with MACCE=2 
and HBP with MACCE=3. As such, this individual is considered as CV FO because her 
multiple and severe CVD put her at very high risk of deleterious effects and possibly 
even death.
Now, both of these patients have CV FO. Nevertheless, the Subject B is clearly  more 
affected and thus ‘more’ at risk for mortality from CVD. This is why a total MACCE 
score was introduced into this study  to allow for quantification of different CVD of each 
subject. Eventually, it may be relevant to see if these total MACCE scores are more 
frequent in specific families. This will allow the characterization of transmission patterns 
of different CVD within each family. Lastly, this new paradigm of a total MACCE score 
will be helpful in creating an update classification of subjects affected by severe CVD, 
e.g. subjects with two or more CV FO (e.g. Subject A) vs. those with three and more 
CV FO (e.g. Subject B).
5.4.4.STATISTICAL ANALYSIS
The main limitation of this study  is that not all 896 subjects were examined. This leaves 
room for adding those to be collected in a later study and perform the statistical analyses 
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that will help  to interpret these results. However, even these collected subjects give a 
good idea and description to stratify the current sample population. We can see exactly 
how each disease, reported diagnosis, outcome and first outcome affects our subjects. As 
such, relative risk and chi square tests were performed to ascertain the validity of our 
findings.
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Conclusion And Future Perspectives
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Conclusion And Future Perspectives
This study provided an insight into affections, of both FO and NFO, in subjects of SLSJ region 
of Quebec. We describe the predominant importance of CV FO in both first outcomes and total 
outcomes when compared to all other diseases, both on the level of subject affections and the 
number of diagnosed outcomes in this specific cohort. When examining CV co-affection with 
non-CV or all other diseases, 67.1% of our sample population was affected by CV FO. In fact, 
our sample showed a threefold risk increase in developing CVD (p<0.0001; χ2=1,575.348), 
while it diminished by  half when compared to non-CVD (p=0.0006; χ2=11.834) in the 
population of SLSJ. Finally, the RR for developing malignancies was twice as unlikely  to 
occur in our sample in contrast  with the same region. Nevertheless, when looking at  them in 
conjunction with CVD, this risk grows twofold in our sample. As such, these results may 
eventually help physicians in their patient approach, and a more effective health system.
In the future, it will be important to pursue the morbidity  data collection for the remaining 
participating subjects, both in Chicoutimi and Montreal. Moreover, once the approval from the 
CAIQ has been obtained, it will be necessary  to obtain from the ISQ the mortality data from 
the families of the participating subject. Thus, we can classify and move ahead with the 
current study by associating high risk of early death to the actual rate of mortality of these 
families. In fact, it will be crucial to link the morbidity  and mortality data with each family 
and observe the prevalence of FO. Furthermore, genetic studies will be necessary in order to 
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link the present phenotypic observation on a genetic level. In fact, genetic predisposition may 
help identify which subjects are more at risk than others.
The mortality  analysis will be ascertained firstly  by  collecting directly obtained information. 
In order to complete this project to the fullest  extent, causes of death will be directly obtained 
from the ISQ according to ICD 9 and ICD 10. The next  step  will comprise the validation with 
the health registry data from the Ministry of Health and Social Services, contained in the 
summary  sheets of all hospitalizations. As for morbidities, the questions raised about consents 
will have to be resolved. Moreover, we will continue doing what was started in this study by 
looking at their medical history in a similar way as for mortalities.
We plan to analyze these mortalities and morbidities, their temporal characteristics and their 
clustering in hypertensive French-Canadian families with or without obesity, using hospital, 
civic death registries and genealogical records from 1950 up to the present. We want to 
describe and study the families and their respective members at high risk of early  mortality. 
This will also be achieved by comparing their phenotypic characteristics within those families 
and also with the families at low risk of early mortality.
Preliminary  data on early mortality  appeared to be more prevalent  in specific families, as 
previously  shown in this population [13]. As discussed above, it may be relevant to review the 
criteria for early  mortality. Are the age intervals for men and women to stringent for analysis? 
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Do they actually  qualify as a segment of population with ‘very’ early  mortality? These are 
important question that should be addressed in the future.
By examining the lethal and non-leathal outcomes of French Canadian families, we want to 
identify the connection between CVD and early  mortality on a clinical and even genetic level. 
This may lead in the future to develop  predictive biomarkers, such as genes, to identify the 
people at risk. Clinical implication may involve a novel development of techniques for the 
patients at risk and a possible orientation towards individualized medicine.
Since our preliminary findings suggest that early  mortality from CVD includes both genetic 
and environmental factors, we will have to test in the future if subjects with FO, especially 
from CV cause, are more at risk of early  mortality than subjects with NFO. If this proves to be 
true, we will try to find the genetic determinants responsible for early mortality  due to FO. 
With a genetic test, we could one day be able to identify  the subjects at risk sooner and treat 
them more efficiently. In fact, this might make the difference between life and death.
To conclude, the study  aims to be a foundation for future analysis, both phenotypic and 
genetic. The data gathered were compiled and we created a database component of the 
participating subjects. Furthermore, we were able to calculate the RR for our sample to 
develop CVD and it was statistically significant. We expect to use it for modeling future 
results for better understanding of CVD risk with a goal to improve prevention and therapy in 
most exposed families.
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